A	C177536	GDC Property Terminology	C125904	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements	A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.	double_hit_lymphoma	double hit lymphoma	
A	C177536	GDC Property Terminology	C132299	Protocol Identifier	A sequence of letters, numbers, or other characters that uniquely identifies a study protocol.	protocol_identifier	protocol identifier	
A	C177536	GDC Property Terminology	C138899	Double-Expressor Lymphoma	A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.	double_expressor_lymphoma	double expressor lymphoma	
A	C177536	GDC Property Terminology	C188372	Exposure Source Indicator	An indicator specifying whether an exposure of a subject to a potentially harmful agent occurred indirectly or occupationally.	exposure_source	exposure source	
A	C177536	GDC Property Terminology	C188373	Asbestos Exposure Mineral Type Indicator	An indicator specifying the type of asbestos mineral that a subject was exposed to.	asbestos_exposure_type	asbestos exposure type	
A	C177536	GDC Property Terminology	C188387	Administered Treatment Clinical Trial Indicator	An indication that the treatment administered is or was part of a clinical trial.	clinical_trial_indicator	clinical trial indicator	
A	C177536	GDC Property Terminology	C188388	Therapeutic Agent Category	A general term used to classify a therapeutic agent. This classification may be based on shared chemical structure, biological function, potential/actual target and/or mechanism of action.	drug_category	drug category	
A	C177536	GDC Property Terminology	C188396	Anatomic Site of Maximum Tumor Bulk	The anatomic site where the portion of the tumor with the largest dimension or diameter is located.	max_tumor_bulk_site	max tumor bulk site	
A	C177536	GDC Property Terminology	C188406	UICC Clinical M Category	The M (metastasis) category value associated with cancer staging data that was determined according to the Union for International Cancer Control (UICC) clinical staging criteria.	uicc_clinical_m	uicc clinical m	
A	C177536	GDC Property Terminology	C188408	UICC Clinical N Category	The N (lymph node involvement) category value associated with cancer staging data that was determined according to the Union for International Cancer Control (UICC) clinical staging criteria.	uicc_clinical_n	uicc clinical n	
A	C177536	GDC Property Terminology	C188409	UICC Clinical Stage	A cancer stage defined according to the Union for International Cancer Control (UICC) clinical staging criteria.	uicc_clinical_stage	uicc clinical stage	
A	C177536	GDC Property Terminology	C188411	UICC Clinical T Category	The T (primary tumor extent) category value associated with cancer staging data that was determined according to the Union for International Cancer Control (UICC) clinical staging criteria.	uicc_clinical_t	uicc clinical t	
A	C177536	GDC Property Terminology	C188415	UICC Pathologic M Category	The M (metastasis) category value associated with cancer staging data that was determined according to the Union for International Cancer Control (UICC) pathologic staging criteria.	uicc_pathologic_m	uicc pathologic m	
A	C177536	GDC Property Terminology	C188429	UICC Pathologic N Category	The N (lymph node involvement) category value associated with cancer staging data that was determined according to the Union for International Cancer Control (UICC) pathologic staging criteria.	uicc_pathologic_n	uicc pathologic n	
A	C177536	GDC Property Terminology	C188446	UICC Pathologic Stage	A cancer stage defined according to the Union for International Cancer Control (UICC) pathologic staging criteria.	uicc_pathologic_stage	uicc pathologic stage	
A	C177536	GDC Property Terminology	C188448	UICC Pathologic T Category	The T (primary tumor extent) category value associated with cancer staging data that was determined according to the Union for International Cancer Control (UICC) pathologic staging criteria.	uicc_pathologic_t	uicc pathologic t	
A	C177536	GDC Property Terminology	C188452	Prostate Zone of Disease Origin	The anatomic zone of the prostate identified as the origin of the disease.	zone_of_origin_prostate	zone of origin prostate	
A	C177536	GDC Property Terminology	C97229	Embolic Agent	A substance used to block an artery, thereby eliminating the blood flow to a specific part of an organ. An embolic agent may cause permanent or temporary blockage depending on the nature of the material used.	embolic_agent	embolic agent	
C	C177536	GDC Property Terminology	C129439	Medulloblastoma Molecular Subtypes	A term that refers to the classification of medulloblastomas according to their molecular characteristics.	medulloblastoma_molecular_classification	medulloblastoma molecular classification	
C	C177536	GDC Property Terminology	C157110	Specify HPV Genotype	A directive to specify the genotype determined by HPV Genotyping.	hpv_strain	hpv strain	
C	C177536	GDC Property Terminology	C181725	Data Analysis Workflow Name	The name of the workflow used to process and/or analyze a data set.	workflow_type	workflow type	
D	C177536	GDC Property Terminology	C15538	Protocol Treatment Arm	A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.	treatment_arm	treatment arm	
D	C177536	GDC Property Terminology	C177573	Radon Exposure	Inhalation of radon gas which is found in rocks, soil and groundwater as a result of radioactive decay of uranium, thorium, or radium in the environment.	radon_exposure	radon exposure	
D	C177536	GDC Property Terminology	C177575	Respirable Crystalline Silica Exposure	Environmental, occupational or consumer-based exposure to respirable particles derived from industrial processing or breakdown of silica-containing materials such as sand, concrete, stone, mortar, bricks,  glass, pottery and ceramics.	respirable_crystalline_silica_exposure	respirable crystalline silica exposure	
D	C177536	GDC Property Terminology	C55816	Asbestos Exposure	Inhalation of asbestos fibers.	asbestos_exposure	asbestos exposure	
A	C177537	GDC Value Terminology	C115248	Methicillin-Resistant Staphylococcus aureus Infection	A bacterial infection that is caused by Staphylococcus aureus that is not susceptible to methicillin.	Methicillin-Resistant Staphylococcus aureus (MRSA) | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C12465	Peripheral Nervous System	That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.	Peripheral nervous system | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C1269	TAG-72 Antigen	Tumor-associated oncofetal glycoprotein 72 (TAG-72) is a high molecular weight (220-400 kD) complex expressed by a wide variety of human adenocarcinomas. This antigen is expressed by a majority of invasive ductal breast carcinomas, and most colon, pancreatic, gastric, esophageal, lung (non-small cell), ovarian and endometrial adenocarcinomas, and on normal secretory endometrium, but not on other normal tissues. It is not expressed by leukemias, lymphomas, sarcomas, mesotheliomas, melanomas or benign tumors. The monoclonal antibodies against TAG-72 have been widely employed for the immunohistochemical analysis of adenocarcinomas as well as for radioimmunoscintigraphy and radioimmunoguided surgery.	TAG-72 | antigen	C268	antigen
A	C177537	GDC Value Terminology	C128570	Peripheral Zone of Prostate	The region of the prostate that is located most superficial and posterior as compared to the other prostate zones. It is located closest to the rectum, and is easily palpated on digital rectal exam. This zone of the prostate surrounds the distal urethra, and is the zone of origin for the vast majority of prostatic cancers.	Peripheral zone | zone_of_origin_prostate	C188452	zone_of_origin_prostate
A	C177537	GDC Value Terminology	C128571	Transition Zone of Prostate	The region of the prostate gland that is located deep to both the central and peripheral zones; it surrounds the proximal urethra, and is the zone of the prostate gland that grows throughout life, most often causing a condition called benign prostatic hypertrophy.	Transition zone | zone_of_origin_prostate	C188452	zone_of_origin_prostate
A	C177537	GDC Value Terminology	C128572	Central Zone of Prostate	This region of the prostate gland that is located between the peripheral and transition zones, surrounding the ejaculatory ducts. It gives rise to a very small percentage of prostate cancers, though these cancers are frequently more aggressive, often resulting in invasion of the seminal vesicles.	Central zone | zone_of_origin_prostate	C188452	zone_of_origin_prostate
A	C177537	GDC Value Terminology	C128829	HHV6 Infection	An infection that is caused by human herpesvirus-6.	Human Herpesvirus-6 (HHV-6) | risk_factor	C17103	risk_factor
A	C177537	GDC Value Terminology	C12964	Connective and Soft Tissue	The supporting connective tissue of an organ.	Connective, subcutaneous and other soft tissues | primary_site || Connective, subcutaneous and other soft tissues, NOS | progression_or_recurrence_anatomic_site || Connective, subcutaneous and other soft tissues, NOS | site_of_resection_or_biopsy || Connective, subcutaneous and other soft tissues, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || progression_or_recurrence_anatomic_site
A	C177537	GDC Value Terminology	C137974	Adnexa	An appendage or accessory structure of an adjacent or related organ.	Adnexa | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C139012	Breast Implant-Associated Anaplastic Large Cell Lymphoma	A rare anaplastic large cell lymphoma that can develop following breast implants. It has been reported in patients with saline-and silicone-filled implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.	Breast implant-associated anaplastic large cell lymphoma | primary_diagnosis	C177621	primary_diagnosis
A	C177537	GDC Value Terminology	C139021	Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract	A clonal T-cell lymphoproliferative disorder that can involve the mucosa in all sites of the gastrointestinal tract, but is most common in the small intestine and colon. The lymphoid cells infiltrate the lamina propria but usually do not show invasion of the epithelium. The clinical course is indolent, but most patients do not respond to conventional chemotherapy. A subset of cases progress to a higher-grade T-cell lymphoma with spread beyond the gastrointestinal tract. (WHO 2017)	Indolent T-cell lymphoproliferative disorder of gastrointestinal tract | primary_diagnosis	C177621	primary_diagnosis
A	C177537	GDC Value Terminology	C156429	Social Drinker	An individual who generally only drinks at social events.	Social Drinker | alcohol_intensity	C126378	alcohol_intensity
A	C177537	GDC Value Terminology	C156806	New Primary Tumor	A finding indicating the development of a tumor in a patient with a history of a previously diagnosed tumor with a different histopathologic profile in another anatomic site as compared to the most recent one.	Prior primary | classification_of_tumor	C174459	classification_of_tumor
A	C177537	GDC Value Terminology	C157522	Overlapping/Multiple Zones of Prostate	A term that indicates involvement of multiple zones of prostate.	Overlapping/multiple zones | zone_of_origin_prostate	C188452	zone_of_origin_prostate
A	C177537	GDC Value Terminology	C159203	Ascites Fluid Sample	A biospecimen of ascitic fluid.	Ascites/peritoneum | max_tumor_bulk_site	C188396	max_tumor_bulk_site
A	C177537	GDC Value Terminology	C159344	Pelvic Peritoneum	A membranous lining of the pelvic organs.	Pelvic Peritoneum | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C159355	Abdominal Peritoneum	A membranous lining of the abdominal cavity and abdominal organs.	Abdominal Peritoneum | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C159717	EBV-Related Lymphoproliferative Disorder	A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.	EBV Lymphoproliferation | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C160198	Unknown Tumor Zone	An indication that the tumor zone is unknown.	Unknown zone | zone_of_origin_prostate	C188452	zone_of_origin_prostate
A	C177537	GDC Value Terminology	C162449	Peptide Receptor Radionuclide Therapy	Treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. It is currently being used to treat neuroendocrine tumors, using octreotide as the targeting peptide.	Peptide Receptor Radionuclide Therapy (PRRT) | treatment_type	C25218	treatment_type
A	C177537	GDC Value Terminology	C16929	Occupational Exposure	The exposure to potentially harmful agents that occurs as a result of one's occupation.	Occupational | exposure_source	C188372	exposure_source
A	C177537	GDC Value Terminology	C173496	Peripheral Blood	Blood drawn from a limb.	Peripheral blood | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C175852	Rezvilutamide	An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, rezvilutamide competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation.	Androgen Receptor Antagonist SHR3680 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175853	Rintodestrant	An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, rintodestrant specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.	SERD G1T48 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175875	Vidutolimod	A virus-like particle (VLP) composed of the Qbeta bacteriophage capsid encapsulating the toll-like receptor 9 (TLR9) agonist G10, an unmethylated CpG-A oligodeoxynucleotide (ODN), with potential immunostimulating and antineoplastic activities. Upon administration of vidutolimod, the VLPs are specifically taken up by and release the oligonucleotide into antigen-presenting cells (APCs), including dendritic cells (DCs). In turn, the oligonucleotide binds to and activates intracellular TLR9. This stimulates immune signaling pathways, induces the innate immune system and may promote the immune system to attack tumor cells. VLPs stimulate the immune system. TLR9, a member of the TLR family, plays a key role in both pathogen recognition and the activation of innate immunity.	VLP-encapsulated TLR9 Agonist CMP-001 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C177573	Radon Exposure	Inhalation of radon gas which is found in rocks, soil and groundwater as a result of radioactive decay of uranium, thorium, or radium in the environment.	Radon | exposure_type	C157103	exposure_type
A	C177537	GDC Value Terminology	C177575	Respirable Crystalline Silica Exposure	Environmental, occupational or consumer-based exposure to respirable particles derived from industrial processing or breakdown of silica-containing materials such as sand, concrete, stone, mortar, bricks,  glass, pottery and ceramics.	Respirable Crystalline Silica | exposure_type	C157103	exposure_type
A	C177537	GDC Value Terminology	C179069	Acazicolcept	An Fc fusion protein comprised of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD) that binds to both inducible T-cell costimulator (ICOS; CD278) and cluster of differentiation 28 (CD28), with potential immunomodulating activity. Upon administration, acazicolcept targets and binds to both CD28 and ICOS expressed on certain T-cells. This prevents the activation of CD28 and ICOS by its ligands, thereby blocking the two T-cell costimulatory pathways and the resulting T-cell activation. CD28 is involved in initiation of the pathogenic process in graft versus host disease (GVHD). Following initial activation, CD28 is often downregulated while ICOS is upregulated, possibly sustaining GVHD. Dual blockade of CD28 and ICOS may be superior to individual blockade of CD28 or ICOS alone.	CD28/ICOS Antagonist ALPN-101 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184829	Gresonitamab	A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody directed against the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, gresonitamab simultaneously binds to both CD3-expressing T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	BiTE Antibody AMG 910 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184834	Pivekimab Sunirine	An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.	Anti-CD123 ADC IMGN632 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184909	Ezurpimtrostat	An orally bioavailable, quinolone-derived, small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1), with potential antineoplastic activity. Upon oral administration, ezurpimtrostat targets and inhibits the activity of PPT1 and induces lysosomal disruption, which results in the inhibition of autophagy and the induction of apoptosis via caspase activation. This may inhibit tumor cell proliferation and tumor growth. PPT1, a lysosomal thioesterase that plays an important role in lysosomal function and autophagy, is overexpressed in certain cancers.	SLCT Inhibitor GNS561 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C186124	Kidney Interpolar Region	The portion of the kidney that is located between the upper and lower poles and contains the renal hilum.	Kidney, Middle | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C188199	Histone H3.X	Histone H3.X (147 aa, ~16 kDa) is encoded by the human H3Y2 gene. This protein may be involved in both transcriptional regulation and the formation of higher order chromatin structures.	H3.X | histone_variant	C177620	histone_variant
A	C177537	GDC Value Terminology	C188218	Neuroendocrine Tumor	A well-differentiated epithelial neuroendocrine neoplasm of low, intermediate, or high grade.	8248/1 | morphology || Apudoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C188229	Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor	A usually indolent neuroendocrine neoplasm that almost exclusively arises in the second part of the duodenum. Rare sites of involvement include jejunum, pylorus, appendix, thymus, and lung. It is a triphasic tumor consisting of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cell-like elements.	8683/0 | morphology || Gangliocytic paraganglioma | primary_daignosis	C176985 || C177621	morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C188292	T1a1 Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion equal or less than 3 mm in depth.	T1a1 | ajcc_clinical_t || T1a1 | ajcc_pathologic_t || T1a1 | uicc_clinical_t || T1a1 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188293	T1a2 Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1a2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion of more than 3.0 mm and equal or less than 5.0 mm in depth.	T1a2 | ajcc_clinical_t || T1a2 | ajcc_pathologic_t || T1a2 | uicc_clinical_t || T1a2 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188294	T1b1 Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates measured stromal invasion measuring more than 5 mm in depth and equal or less than 2 cm in greatest dimension.	T1b1 | ajcc_clinical_t || T1b1 | ajcc_pathologic_t || T1b1 | uicc_clinical_t || T1b1 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188295	T1b2 Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth. The definition of T1b2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates stromal invasion measuring more than 2 cm and equal or less than 4 cm in greatest dimension.	T1b2 | ajcc_clinical_t || T1b2 | ajcc_pathologic_t || T1b2 | uicc_clinical_t || T1b2 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188296	T2a1 Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T2a1 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates involvement limited to the upper two-thirds of the vagina without parametrial invasion measuring 4.0 cm or less in greatest dimension.	T2a1 | ajcc_clinical_t || T2a1 | ajcc_pathologic_t || T2a1 | uicc_clinical_t || T2a1 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188297	T2a2 Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T2a2 TNM finding depends on the specific type of cancer to which it refers: for example, for cervical carcinoma it indicates involvement limited to the upper two-thirds of the vagina without parametrial invasion measuring more than 4.0 cm in greatest dimension.	T2a2 | ajcc_clinical_t || T2a2 | ajcc_pathologic_t || T2a2 | uicc_clinical_t || T2a2 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188298	T4e Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4e TNM finding depends on the specific type of cancer that it refers: for example, for choroidal and ciliary body melanoma it indicates any tumor size category with extraocular extension more than 5 mm in largest diameter.	T4e | ajcc_clinical_t || T4e | ajcc_pathologic_t || T4e | uicc_clinical_t || T4e | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
A	C177537	GDC Value Terminology	C188299	Stage M2	A stage term that refers to a central nervous system embryonal malignant tumor (e.g., atypical teratoid/rhabdoid tumor, medulloblastoma, pineoblastoma) in which gross nodular tumor seeding is detected in the cerebellar/cerebral subarachnoid space or in the third or lateral ventricles.	M2 | ajcc_pathologic_m || M2 | uicc_pathologic_m	C177607 || C188415	ajcc_pathologic_m || uicc_pathologic_m
A	C177537	GDC Value Terminology	C188301	M1d Stage Finding	A TNM finding indicating the spread of cancer to distant anatomic sites. The definition of M1d TNM finding depends on the specific type of cancer to which it refers: for example, for cutaneous melanoma it indicates distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease. LDH level not recorded or unspecified.	M1d | ajcc_pathologic_m || M1d | uicc_pathologic_m	C177607 || C188415	ajcc_pathologic_m || uicc_pathologic_m
A	C177537	GDC Value Terminology	C188314	Chronic Phase Primary Myelofibrosis	Primary myelofibrosis characterized by the presence of less than 10% blasts in the peripheral blood or bone marrow.	Chronic idiopathic myelofibrosis | primary_diagnosis	C177621	primary_diagnosis
A	C177537	GDC Value Terminology	C188349	Percent Follicular Component Less than or Equal to 10 Percent	A semi-quantitative microscopic finding indicating that less than or equal to 10 percent of the area of a tissue section has follicular structures.	Percent follicular component <= 10% | additional_pathology_findings	C158809	additional_pathology_findings
A	C177537	GDC Value Terminology	C188350	Percent Follicular Component Greater than 10 Percent	A semi-quantitative microscopic finding indicating more than 10 percent of the area of a tissue section has follicular structures.	Percent follicular component > 10% | additional_pathology_findings	C158809	additional_pathology_findings
A	C177537	GDC Value Terminology	C188351	PD-L1 Combined Positive Score 20	A quantitative immunohistochemical finding indicating that the number of all PD-L1-expressing cells divided by the total number of viable tumor cells in a sample multiplied by 100 is 20.	PD-L1 CPS (223C LDT) - 20% | additional_pathology_findings	C158809	additional_pathology_findings
A	C177537	GDC Value Terminology	C188352	N6-Methyladenine Enriched RNA	A biological sample comprised of RNA that has subjected to an immunoprecipitation procedure using an antibody designed to select for sequences containing N6-methyladenine modifications.	m6A Enriched RNA | analyte_type	C156434	analyte_type
A	C177537	GDC Value Terminology	C188353	Staphylococcal Osteomyelitis	Osteomyelitis resulting from an infection with Staphylococcus.	Staph Osteomyelitis | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C188367	Persistent Locoregional Disease	A disease that persists locally and/or regionally in regards to the site of origin despite treatment.	PLD-Persistent Locoregional Disease | disease_response	C50995	disease_response
A	C177537	GDC Value Terminology	C188368	ELN Adverse-Risk Category	A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating unfavorable cytogenetics and a poor prognosis, which includes an unfavorable disease response to conventional consolidation therapy. In these cases, autologous or allogeneic hematopoietic stem cell transplantation is recommended.	Adverse | eln_risk_classification	C177562	eln_risk_classification
A	C177537	GDC Value Terminology	C188369	ELN Favorable-Risk Category	A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating a favorable prognosis following conventional consolidation therapy.	Favorable | eln_risk_classification	C177562	eln_risk_classification
A	C177537	GDC Value Terminology	C188370	ELN Intermediate-Risk Category	A risk stratification category based on molecular genetic profiling of a subject with acute myeloid leukemia indicating an intermediate chance for relapse following treatment and remission. Subjects in this risk group are recommended to receive conventional consolidation therapy followed by allogeneic hematopoietic stem cell transplantation to achieve remission.	Intermediate | eln_risk_classification	C177562	eln_risk_classification
A	C177537	GDC Value Terminology	C188371	N6-Methyladenine RNA Immunoprecipitation-Sequencing	A method used to sequence N6-methyladenine (m6A)-modified RNA. Briefly, an RNA sample is subjected to immunoprecipitation using an antibody that specifically enriches m6A RNA, the m6A enriched RNA is reverse-transcribed to produce the complimentary DNA (cDNA) strand and the cDNA is subjected to sequencing.	m6A MeRIP-Seq | experimental_strategy || m6A MeRIP-Seq | library_strategy	C177618 || C43622	library_strategy || experimental_strategy
A	C177537	GDC Value Terminology	C188376	Secondary Exposure Indicator	An indication that a subject was indirectly exposed to potentially harmful agent.	Secondary | exposure_source	C188372	exposure_source
A	C177537	GDC Value Terminology	C188386	Maximum Tumor Bulk No Known Nodal Involvement	A response indicating that no lymph node involvement was detected when the location of a tumor bulk maximum was examined.	No known nodal involvement | max_tumor_bulk_site	C188396	max_tumor_bulk_site
A	C177537	GDC Value Terminology	C24863	TLR2 Gene	This gene plays a role in pathogen recognition and mediates the host response to gram-positive bacteria and yeast.	TLR2 | gene_symbol || TLR2 | second_gene_symbol	C171253 || C173595	second_gene_symbol || gene_symbol
A	C177537	GDC Value Terminology	C26990	Transplanted Kidney Complication	A disease or disorder that is associated with a transplanted kidney.	Transplanted kidney | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C27566	Non-Neoplastic Thyroid Gland Disorder	A non-neoplastic disorder that affects the thyroid gland.  Representative examples include hyperthyroidism, hypothyroidism, thyroiditis, and thyroid gland abscess.	Thyroid Disease, Non-Cancer | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C27582	Central Nervous System Infectious Disorder	An infectious process that affects the brain and/or spinal cord. Representative examples include encephalitis, poliomyelitis, arachnoiditis, and meningitis.	CNS Infection | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C27701	Secondary Myelofibrosis	Myelofibrosis that develops in patients with a history of hematologic malignancies or toxic injury to the bone marrow.	Myelofibrosis as a result of myeloproliferative disease | primary_diagnosis	C177621	primary_diagnosis
A	C177537	GDC Value Terminology	C28254	Milliliter	A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume.	mL | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C29816	Crocidolite Asbestos	A naturally occurring, blue, fibrous amphibole asbestos mineral. Crocidolite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Crocidolite asbestos is a known human carcinogen. (NCI05)	Crocidolite | asbestos_exposure_type	C188373	asbestos_exposure_type
A	C177537	GDC Value Terminology	C30103	Stable	Subject to little fluctuation; showing little if any change.	Stable | test_result	C36292	test_result
A	C177537	GDC Value Terminology	C32959	Left Fallopian Tube	The fallopian tube that extends from the uterus to the ovary in the left side of the pelvic cavity.	Fallopian Tube, Left | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C32969	Left Ovary	The ovary that is located in the left side of the pelvis.	Ovary, Left | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C33301	Perineum	The area located between the anus and vulva in females, and anus and scrotum in males.	Perineum | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C33475	Right Fallopian Tube	The fallopian tube that extends from the uterus to the ovary in the right side of the pelvic cavity.	Fallopian Tube, Right | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C33487	Right Ovary	The ovary that is located in the right side of the pelvis.	Ovary, Right | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C36290	Chemical Exposure	Contact with a chemical substance through touch, inhalation, or ingestion.	Chemical | exposure_type	C157103	exposure_type
A	C177537	GDC Value Terminology	C38705	Absorbable Gelatin Sponge	A sterile hemostatic agent composed of purified porcine-derived gelatin.  In regional chemotherapy, absorbable gelatin sponge may be used to embolize arteries in the region of a tumor in order to block or retard blood flow; this blockage results in a locally increased concentration of chemotherapeutic agents delivered to the tumor when chemotherapeutic agents are infused into the embolized arterial circulation upstream of the blockage.	Gelfoam | embolic_agent	C97229	embolic_agent
A	C177537	GDC Value Terminology	C39291	HHV8 Infection	An infectious process caused by the human herpesvirus 8. This infection is associated with Kaposi sarcoma.	Human Herpesvirus-8 (HHV-8) | risk_factor	C17103	risk_factor
A	C177537	GDC Value Terminology	C45527	Amosite Asbestos	A naturally occurring, fibrous amphibole asbestos mineral with a color ranging from gray to greenish-brown. Amosite is used extensively in industry for various purposes. Chronic inhalation of its dust may cause asbestosis and increases the risk of respiratory tract cancer, mesothelioma and other lung cancers. Amosite asbestos is a known human carcinogen. (NCI05)	Amosite | asbestos_exposure_type	C188373	asbestos_exposure_type
A	C177537	GDC Value Terminology	C48152	Microgram	A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram.	ug | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C48511	Millicurie	A unit of radioactivity equal to one thousandth of a curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.	mCi | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C48512	Milliequivalent	A unit of relative amount of a substance equal to one thousandth of an equivalent weight.	mEq | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C48552	Wafer Dosing Unit	A dosing unit equal to the amount of active ingredient(s) contained in a wafer.	Wafer | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C487	Ethiodized Oil	A synthetic iodine addition product of the ethyl ester of the fatty acids of poppy seed oil. Ethiodized oil contains 37% organically bound iodine and is used as a diagnostic radiopaque medium or, labeled with I-131, as an antineoplastic agent. Selectively retained in tumor vessels for long periods, ethiodized oil is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodol can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.	Lipiodol | embolic_agent	C97229	embolic_agent
A	C177537	GDC Value Terminology	C50791	Urinary Tract Infection	A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.	Urinary Tract Infection | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C521	Therapeutic Glucocorticoid	Synthetically derived forms of the naturally occurring Glucocorticoids.	Glucocorticoid | drug_category	C188388	drug_category
A	C177537	GDC Value Terminology	C530	Recombinant Growth Factor	Formulated therapeutic proteins that are either isolated from endogenous sources or manufactured in a laboratory.  Growth factors bind to specific receptors expressed by various cell types, thereby stimulating cell differentiation and/or proliferation. (NCI04)	Growth factor | drug_category	C188388	drug_category
A	C177537	GDC Value Terminology	C54621	Synchronous Lesion	Two or more primary lesions that are diagnosed at the same time in the same patient, or soon after the diagnosis of the first primary lesion.	Synchronous primary | classification_of_tumor	C174459	classification_of_tumor
A	C177537	GDC Value Terminology	C55816	Asbestos Exposure	Inhalation of asbestos fibers.	Asbestos | exposure_type	C157103	exposure_type
A	C177537	GDC Value Terminology	C62554	Poly (ADP-Ribose) Polymerase Inhibitor	Any substance that inhibits Poly (ADP-Ribose) polymerase, an enzyme involved in detecting DNA single strand breaks and the initiation of DNA repair. Inhibition of Poly (ADP-Ribose) polymerase has direct cytotoxic effects by inhibiting DNA repair and causing cell death.	PARP inhibitor | drug_category	C188388	drug_category
A	C177537	GDC Value Terminology	C62656	Prothrombin Time	A measurement of the clotting time of plasma recalcified in the presence of excess tissue thromboplastin; it is a measure of the extrinsic pathway of coagulation. It is used to determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage and vitamin K status. Factors measured are fibrinogen, prothrombin, and factors V, VII, and X.	Prothrombin Time | laboratory_test	C25294	laboratory_test
A	C177537	GDC Value Terminology	C64774	Area Under Curve	The area between the x-axis and the curve given by the integrand. It is equal to the definite integral of a function. In the field of pharmacokinetics, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in plasma against time. AUC is usually given for the time interval zero to infinity, and other time intervals are indicated.	AUC | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C66974	Milligram per Square Meter per Day	A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours.	mg/m2/day | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C66976	Milligram per Kilogram per Day	A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours.	mg/kg/day | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67282	Gram per Square Meter	A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters.	g/m2 | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67312	Microgram per Square Meter	A metric unit of areal density equal to approximately 2.94935E-8 ounce per square yard. Also used as a dose calculation unit.	ug/m2 | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67316	Milliinternational Unit	A unit equal to one-thousandth of an international unit.	mIU | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67372	Gram per 24 Hours	A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours.	g/day | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67379	International Unit per Kilogram	A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in kilograms. It is also used as a dose calculation unit expressed in International Units of biological activity per one kilogram of body mass.	IU/kg | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67380	International Unit per Milligram	A unit of measure of quantity of substance per unit mass, expressed in terms of International Units per milligram. (CDISC)	IU/mg | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67399	Milligram per 24 Hours	A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours.	mg/24 hr | test_units || mg/day | treatment_dose_units	C166199 || C67415	treatment_dose_units || test_units
A	C177537	GDC Value Terminology	C67401	Milligram per Kilogram	A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.	mg/kg | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67402	Milligram per Square Meter	A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.	mg/m2 | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C67404	Milligram per Week	A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week.	mg/wk | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C71147	PVA Microporous Hydrospheres	An embolic material composed of microspheres of polyvinyl alcohol (PVA) polymers. These water-soluble, compressible microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as a drug delivery vehicle during embolization of tumor vasculature.	PVA Particles | embolic_agent	C97229	embolic_agent
A	C177537	GDC Value Terminology	C74611	Erythrocyte Sedimentation Rate Measurement	A quantitative measurement of the distance that red blood cells travel in one hour in a sample of unclotted blood.	Erythrocyte Sedimentation Rate | laboratory_test	C25294	laboratory_test
A	C177537	GDC Value Terminology	C74919	Cells per Milliliter	A unit of cell concentration expressed in cells per unit of volume equal to one milliliter.	cells/mL | test_units	C67415	test_units
A	C177537	GDC Value Terminology	C77995	Rivaroxaban	An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.	Rivaroxaban | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C80971	Canakinumab	A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.	Canakinumab | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C83887	Linagliptin	A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.	Linagliptin | diabetes_treatment_type	C99532	diabetes_treatment_type
A	C177537	GDC Value Terminology	C88148	Milligram per Square Meter per Week	A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.	mg/m2/wk | treatment_dose_units	C166199	treatment_dose_units
A	C177537	GDC Value Terminology	C93179	Upper Pole of Kidney	The pole of the kidney located in the uppermost region of the kidney.	Kidney, Upper Pole | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C93180	Lower Pole of Kidney	The pole of the kidney located in the lowest region of the kidney.	Kidney, Lower Pole | sites_of_involvement	C173263	sites_of_involvement
A	C177537	GDC Value Terminology	C97230	Embolic Bead	An embolic agent that is in the form of a small sphere.	Spherical Particles | embolic_agent	C97229	embolic_agent
A	C177537	GDC Value Terminology	C97233	Plastic Embolic Bead	An embolic bead that is made from a plastic-like resin or polymer.	Plastic Beads | embolic_agent	C97229	embolic_agent
C	C177537	GDC Value Terminology	C102904	Human Papillomavirus-31	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-31 is associated with a high risk for cervical intraepithelial neoplasia.	HPV31 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C102996	Human Papillomavirus-33	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-33 is associated with a high risk for cervical intraepithelial neoplasia.	HPV33 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C102997	Human Papillomavirus-35	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-35 is associated with a high risk for cervical intraepithelial neoplasia.	HPV35 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C102998	Human Papillomavirus-39	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-39 is associated with a high risk for cervical intraepithelial neoplasia.	HPV39 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C102999	Human Papillomavirus-45	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-45 is associated with a high risk for cervical intraepithelial neoplasia.	HPV45 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103000	Human Papillomavirus-51	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-51 is associated with a high risk for cervical intraepithelial neoplasia.	HPV51 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103001	Human Papillomavirus-52	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-52 is associated with a high risk for cervical intraepithelial neoplasia.	HPV52 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103003	Human Papillomavirus-56	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-56 is associated with a high risk for cervical intraepithelial neoplasia.	HPV56 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103004	Human Papillomavirus-58	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-58 is associated with a high risk for cervical intraepithelial neoplasia.	HPV58 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103005	Human Papillomavirus-59	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-59 is associated with a high risk for cervical intraepithelial neoplasia.	HPV59 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103006	Human Papillomavirus-66	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-66 is associated with a high risk for cervical intraepithelial neoplasia.	HPV66 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103007	Human Papillomavirus-68	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-68 may be associated with a high risk for cervical intraepithelial neoplasia.	HPV68 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C103008	Human Papillomavirus-73	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-73 may be associated with a high risk for cervical intraepithelial neoplasia.	HPV73 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C111901	Pelabresib Anhydrous	The anhydrous form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.	BET Inhibitor CPI-0610 | therapeutic_agents || Pelabresib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C113162	Mivavotinib	An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.	Mivavotinib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C113330	BRAF Inhibitor FORE8394	An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, BRAF inhibitor FORE8394 selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.	BRAF Inhibitor PLX8394 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C119740	Selicrelumab	A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.	Selicrelumab | therapeutic_agents || CD40 Agonist Monoclonal Antibody CP-870,893 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12285	Upper Lobe of the Lung	The lobe of the right lung that lies above the oblique and horizontal fissures and includes the apical, posterior and anterior bronchopulmonary segments; in the left lung, the lobe lies above the oblique fissure and contains the apicoposterior, anterior, superior lingular and inferior lingular segments.	Upper lobe, lung | progression_or_recurrence_anatomic_site || Upper lobe, lung | site_of_resection_or_biopsy || Upper lobe, lung | sites_of_involvement || Upper lobe, lung | tissue_or_organ_of_origin	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12286	Middle Lobe of the Right Lung	The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure.	Middle lobe, lung | progression_or_recurrence_anatomic_site || Middle lobe, lung | site_of_resection_or_biopsy || Middle lobe, lung | sites_of_involvement || Middle lobe, lung | tissue_or_organ_of_origin	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12287	Lower Lobe of the Lung	The bottom most subdivision of either the right or left lung.	Lower lobe, lung | progression_or_recurrence_anatomic_site || Lower lobe, lung | site_of_resection_or_biopsy || Lower lobe, lung | sites_of_involvement || Lower lobe, lung | tissue_or_organ_of_origin	C156421 || C156422 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12290	Mandible	The lower jaw bone holding the lower teeth.	Mandible | biospecimen_anatomic_site || Mandible | max_tumor_bulk_site || Mandible | progression_or_recurrence_anatomic_site || Mandible | site_of_resection_or_biopsy || Mandible | sites_of_involvement || Mandible | tissue_or_organ_of_origin || Mandible | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12298	Retroperitoneum	The back of the abdomen where the kidneys lie and the great blood vessels run.	Retroperitoneum | biospecimen_anatomic_site || Retroperitoneum | metastasis_at_diagnosis_site || Retroperitoneum | progression_or_recurrence_anatomic_site || Retroperitoneum | site_of_resection_or_biopsy || Retroperitoneum | sites_of_involvement || Retroperitoneum | tissue_or_organ_of_origin || Retroperitoneum | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12311	Cervix Uteri	The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.	Cervix | biospecimen_anatomic_site || Cervix | sites_of_involvement || Cervix | treatment_anatomic_site || Cervix uteri | primary_site || Cervix uteri | progression_or_recurrence_anatomic_site || Cervix uteri | site_of_resection_or_biopsy || Cervix uteri | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12328	Epididymis	A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis.	Epididymis | biospecimen_anatomic_site || Epididymis | progression_or_recurrence_anatomic_site || Epididymis | site_of_resection_or_biopsy || Epididymis | sites_of_involvement || Epididymis | tissue_or_organ_of_origin || Epididymis | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12347	Orbit	The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.	Ocular Orbits | biospecimen_anatomic_site || Ocular Orbits | treatment_anatomic_site || Ocular orbits | sites_of_involvement || Orbit, NOS | progression_or_recurrence_anatomic_site || Orbit, NOS | site_of_resection_or_biopsy || Orbit, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12366	Bone	The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.	Bone | biospecimen_anatomic_site || Bone | metastasis_at_diagnosis_site || Bone | treatment_anatomic_site || Bone, NOS | progression_or_recurrence_anatomic_site || Bone, NOS | site_of_resection_or_biopsy || Bone, NOS | sites_of_involvement || Bone, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12377	Gallbladder	A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods.	Gallbladder | biospecimen_anatomic_site || Gallbladder | primary_site || Gallbladder | progression_or_recurrence_anatomic_site || Gallbladder | site_of_resection_or_biopsy || Gallbladder | sites_of_involvement || Gallbladder | tissue_or_organ_of_origin || Gallbladder | treatment_anatomic_site	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12380	Appendix	Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.	Appendix | biospecimen_anatomic_site || Appendix | max_tumor_bulk_site || Appendix | progression_or_recurrence_anatomic_site || Appendix | site_of_resection_or_biopsy || Appendix | sites_of_involvement || Appendix | tissue_or_organ_of_origin || Appendix | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12382	Colon	The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.	Colon | biospecimen_anatomic_site || Colon | max_tumor_bulk_site || Colon | metastasis_at_diagnosis_site || Colon | primary_site || Colon | treatment_anatomic_site || Colon, NOS | progression_or_recurrence_anatomic_site || Colon, NOS | site_of_resection_or_biopsy || Colon, NOS | sites_of_involvement || Colon, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C123825	Mulnitorsen	A proprietary antisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA), with potential antineoplastic activity. Upon administration, mulnitorsen binds to ncmtRNA, which is overexpressed in rapidly proliferating cells, such as cancer cells, and not expressed in resting cells. This may decrease the expression of the ncmtRNA, which may inhibit cell proliferation and eventually induce apoptosis in susceptible cancer cells. The proprietary mitochondrial RNA (mtRNA) belongs to the family of non-coding RNAs (ncRNA); it contains an inverted repeat (IR) of 815 nucleotides (nt), which can form a covalent link to the 5' end of the mitochondrial 16S ribosomal RNA (16S mtrRNA).	ncmtRNA Oligonucleotide Andes-1537 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12384	Sigmoid Colon	The portion of the colon that connects to the descending colon above and the rectum below.	Sigmoid Colon | biospecimen_anatomic_site || Sigmoid Colon | treatment_anatomic_site || Sigmoid colon | progression_or_recurrence_anatomic_site || Sigmoid colon | site_of_resection_or_biopsy || Sigmoid colon | sites_of_involvement || Sigmoid colon | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12385	Transverse Colon	The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.	Transverse Colon | biospecimen_anatomic_site || Transverse Colon | treatment_anatomic_site || Transverse colon | progression_or_recurrence_anatomic_site || Transverse colon | site_of_resection_or_biopsy || Transverse colon | sites_of_involvement || Transverse colon | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12386	Small Intestine	The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine.	Small Bowel | biospecimen_anatomic_site || Small Bowel | treatment_anatomic_site || Small Intestine | metastasis_at_diagnosis_site || Small intestine | max_tumor_bulk_site || Small intestine | primary_site || Small intestine | sites_of_involvement || Small intestine, NOS | progression_or_recurrence_anatomic_site || Small intestine, NOS | site_of_resection_or_biopsy || Small intestine, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12387	Ileum	The final section of the small intestine.	Ileum | biospecimen_anatomic_site || Ileum | progression_or_recurrence_anatomic_site || Ileum | site_of_resection_or_biopsy || Ileum | tissue_or_organ_of_origin || Ileum | treatment_anatomic_site || Iliac | max_tumor_bulk_site	C156421 || C156422 || C171435 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12389	Esophagus	The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.	Esophagus | biospecimen_anatomic_site || Esophagus | metastasis_at_diagnosis_site || Esophagus | primary_site || Esophagus | sites_of_involvement || Esophagus | treatment_anatomic_site || Esophagus, NOS | progression_or_recurrence_anatomic_site || Esophagus, NOS | site_of_resection_or_biopsy || Esophagus, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12390	Rectum	The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.	Rectum | biospecimen_anatomic_site || Rectum | primary_site || Rectum | sites_of_involvement || Rectum | treatment_anatomic_site || Rectum, NOS | progression_or_recurrence_anatomic_site || Rectum, NOS | site_of_resection_or_biopsy || Rectum, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12391	Stomach	An organ located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine. The stomach is the primary organ of food digestion.	Stomach | biospecimen_anatomic_site || Stomach | max_tumor_bulk_site || Stomach | metastasis_at_diagnosis_site || Stomach | primary_site || Stomach | sites_of_involvement || Stomach | treatment_anatomic_site || Stomach, NOS | progression_or_recurrence_anatomic_site || Stomach, NOS | site_of_resection_or_biopsy || Stomach, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C123912	Sovleplenib	An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration of sovleplenib, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.	Syk Inhibitor HMPL-523 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12392	Liver	A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.	Liver | biospecimen_anatomic_site || Liver | max_tumor_bulk_site || Liver | metastasis_at_diagnosis_site || Liver | progression_or_recurrence_anatomic_site || Liver | site_of_resection_or_biopsy || Liver | sites_of_involvement || Liver | tissue_or_organ_of_origin || Liver | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12393	Pancreas	An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.	Pancreas | biospecimen_anatomic_site || Pancreas | max_tumor_bulk_site || Pancreas | metastasis_at_diagnosis_site || Pancreas | primary_site || Pancreas | sites_of_involvement || Pancreas | treatment_anatomic_site || Pancreas, NOS | progression_or_recurrence_anatomic_site || Pancreas, NOS | site_of_resection_or_biopsy || Pancreas, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12394	Ear	A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.	Ear | biospecimen_anatomic_site || Ear | sites_of_involvement || Ear | treatment_anatomic_site	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12400	Thyroid Gland	An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.	Thyroid | biospecimen_anatomic_site || Thyroid | max_tumor_bulk_site || Thyroid | sites_of_involvement || Thyroid | treatment_anatomic_site || Thyroid gland | primary_site || Thyroid gland | progression_or_recurrence_anatomic_site || Thyroid gland | site_of_resection_or_biopsy || Thyroid gland | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12401	Eye	The organ of sight or vision.	Eye | biospecimen_anatomic_site || Eye | sites_of_involvement || Eye | treatment_anatomic_site || Eye, NOS | progression_or_recurrence_anatomic_site || Eye, NOS | site_of_resection_or_biopsy || Eye, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12403	Fallopian Tube	One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.	Fallopian Tube | biospecimen_anatomic_site || Fallopian Tube | treatment_anatomic_site || Fallopian Tube, NOS | sites_of_involvement || Fallopian tube | progression_or_recurrence_anatomic_site || Fallopian tube | site_of_resection_or_biopsy || Fallopian tube | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12404	Ovary	One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.	Ovary | biospecimen_anatomic_site || Ovary | max_tumor_bulk_site || Ovary | metastasis_at_diagnosis_site || Ovary | primary_site || Ovary | progression_or_recurrence_anatomic_site || Ovary | site_of_resection_or_biopsy || Ovary | tissue_or_organ_of_origin || Ovary | treatment_anatomic_site || Ovary, NOS | sites_of_involvement	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12405	Uterus	A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.	Uterus | biospecimen_anatomic_site || Uterus | sites_of_involvement || Uterus | treatment_anatomic_site || Uterus, NOS | primary_site || Uterus, NOS | progression_or_recurrence_anatomic_site || Uterus, NOS | site_of_resection_or_biopsy || Uterus, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12407	Vagina	The female genital canal, extending from the uterus to the vulva.	Vagina | biospecimen_anatomic_site || Vagina | hysterectomy_margins_involved || Vagina | primary_site || Vagina | sites_of_involvement || Vagina | treatment_anatomic_site || Vagina, NOS | progression_or_recurrence_anatomic_site || Vagina, NOS | site_of_resection_or_biopsy || Vagina, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177594 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || hysterectomy_margins_involved || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12410	Prostate Gland	The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.	Prostate | biospecimen_anatomic_site || Prostate | sites_of_involvement || Prostate | treatment_anatomic_site || Prostate gland | primary_site || Prostate gland | progression_or_recurrence_anatomic_site || Prostate gland | site_of_resection_or_biopsy || Prostate gland | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12412	Testis	Either of the paired male reproductive glands that produce the male germ cells and the male hormones.	Testes | sites_of_involvement || Testis | biospecimen_anatomic_site || Testis | primary_site || Testis | treatment_anatomic_site || Testis, NOS | progression_or_recurrence_anatomic_site || Testis, NOS | site_of_resection_or_biopsy || Testis, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12414	Bladder	The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.	Bladder | biospecimen_anatomic_site || Bladder | hysterectomy_margins_involved || Bladder | metastasis_at_diagnosis_site || Bladder | primary_site || Bladder | treatment_anatomic_site || Bladder, NOS | progression_or_recurrence_anatomic_site || Bladder, NOS | site_of_resection_or_biopsy || Bladder, NOS | sites_of_involvement || Bladder, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177594 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || hysterectomy_margins_involved || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12415	Kidney	One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secrete metabolic products and minerals from the blood, thus maintaining homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.	Kidney | biospecimen_anatomic_site || Kidney | max_tumor_bulk_site || Kidney | metastasis_at_diagnosis_site || Kidney | primary_site || Kidney | treatment_anatomic_site || Kidney, NOS | progression_or_recurrence_anatomic_site || Kidney, NOS | site_of_resection_or_biopsy || Kidney, NOS | sites_of_involvement || Kidney, NOS | tissue_or_organ_of_origin || Renal | margins_involved_site	C156421 || C156422 || C158874 || C171435 || C173263 || C177569 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || margins_involved_site || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12420	Larynx	The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.	Larynx | biospecimen_anatomic_site || Larynx | primary_site || Larynx | treatment_anatomic_site || Larynx, NOS | progression_or_recurrence_anatomic_site || Larynx, NOS | site_of_resection_or_biopsy || Larynx, NOS | sites_of_involvement || Larynx, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12421	Oral Cavity	The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.	Buccal Cavity | biospecimen_anatomic_site || Buccal Cavity | treatment_anatomic_site || Mouth | sites_of_involvement || Mouth, NOS | progression_or_recurrence_anatomic_site || Mouth, NOS | site_of_resection_or_biopsy || Mouth, NOS | tissue_or_organ_of_origin || Oral Cavity | biospecimen_anatomic_site || Oral Cavity | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12422	Tongue	The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.	Tongue | biospecimen_anatomic_site || Tongue | sites_of_involvement || Tongue | treatment_anatomic_site || Tongue, NOS | progression_or_recurrence_anatomic_site || Tongue, NOS | site_of_resection_or_biopsy || Tongue, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12423	Nasopharynx	The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.	Nasopharynx | biospecimen_anatomic_site || Nasopharynx | primary_site || Nasopharynx | sites_of_involvement || Nasopharynx | treatment_anatomic_site || Nasopharynx, NOS | progression_or_recurrence_anatomic_site || Nasopharynx, NOS | site_of_resection_or_biopsy || Nasopharynx, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12426	Salivary Gland	An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity.	Major salivary gland, NOS | progression_or_recurrence_anatomic_site || Major salivary gland, NOS | site_of_resection_or_biopsy || Major salivary gland, NOS | tissue_or_organ_of_origin || Salivary Gland | biospecimen_anatomic_site || Salivary Gland | treatment_anatomic_site || Salivary gland | sites_of_involvement	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12427	Parotid Gland	The largest of the three paired salivary glands, located in front of the ear.	Parotid Gland | biospecimen_anatomic_site || Parotid Gland | treatment_anatomic_site || Parotid gland | max_tumor_bulk_site || Parotid gland | primary_site || Parotid gland | progression_or_recurrence_anatomic_site || Parotid gland | site_of_resection_or_biopsy || Parotid gland | sites_of_involvement || Parotid gland | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12428	Trachea	The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi.	Trachea | primary_site || Trachea | progression_or_recurrence_anatomic_site || Trachea | site_of_resection_or_biopsy || Trachea | sites_of_involvement || Trachea | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C173263 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || sites_of_involvement || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C12431	Bone Marrow	The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.	Bone Marrow | biospecimen_anatomic_site || Bone Marrow | biospecimen_type || Bone Marrow | metastasis_at_diagnosis_site || Bone Marrow | treatment_anatomic_site || Bone marrow | max_tumor_bulk_site || Bone marrow | progression_or_recurrence_anatomic_site || Bone marrow | site_of_resection_or_biopsy || Bone marrow | sites_of_involvement || Bone marrow | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729 || C83315	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site || biospecimen_type
C	C177537	GDC Value Terminology	C12432	Spleen	An organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule. It is located in the left hypochondriac region. Its functions include lymphocyte production, blood cell storage, and blood cell destruction.	Spleen | biospecimen_anatomic_site || Spleen | metastasis_at_diagnosis_site || Spleen | progression_or_recurrence_anatomic_site || Spleen | site_of_resection_or_biopsy || Spleen | sites_of_involvement || Spleen | tissue_or_organ_of_origin || Spleen | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12438	Central Nervous System	The part of the nervous system that consists of the brain, spinal cord, and meninges.	Central Nervous System | biospecimen_anatomic_site || Central Nervous System | metastasis_at_diagnosis_site || Central Nervous System | treatment_anatomic_site || Central nervous system | sites_of_involvement	C171435 || C173263 || C177625 || C70729	biospecimen_anatomic_site || sites_of_involvement || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12439	Brain	An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.	Brain | biospecimen_anatomic_site || Brain | max_tumor_bulk_site || Brain | metastasis_at_diagnosis_site || Brain | primary_site || Brain | treatment_anatomic_site || Brain, NOS | progression_or_recurrence_anatomic_site || Brain, NOS | site_of_resection_or_biopsy || Brain, NOS | sites_of_involvement || Brain, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12468	Lung	One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.	Lung | biospecimen_anatomic_site || Lung | max_tumor_bulk_site || Lung | metastasis_at_diagnosis_site || Lung | treatment_anatomic_site || Lung, NOS | progression_or_recurrence_anatomic_site || Lung, NOS | site_of_resection_or_biopsy || Lung, NOS | sites_of_involvement || Lung, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12469	Pleura	The tissue that lines the wall of the thoracic cavity and the surface of the lungs.	Pleura | biospecimen_anatomic_site || Pleura | metastasis_at_diagnosis_site || Pleura | sites_of_involvement || Pleura | treatment_anatomic_site || Pleura, NOS | progression_or_recurrence_anatomic_site || Pleura, NOS | site_of_resection_or_biopsy || Pleura, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12470	Skin	An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.	Skin | biospecimen_anatomic_site || Skin | biospecimen_type || Skin | metastasis_at_diagnosis_site || Skin | primary_site || Skin | sites_of_involvement || Skin | treatment_anatomic_site || Skin, NOS | progression_or_recurrence_anatomic_site || Skin, NOS | site_of_resection_or_biopsy || Skin, NOS | tissue_or_organ_of_origin || Skin, total | treatment_anatomic_site	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C70729 || C83315	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site || biospecimen_type
C	C177537	GDC Value Terminology	C12471	Soft Tissue	A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.	Soft Tissue | biospecimen_anatomic_site || Soft Tissue | biospecimen_type || Soft Tissue | metastasis_at_diagnosis_site || Soft Tissue | treatment_anatomic_site || Soft tissue | sites_of_involvement || Soft tissue (muscle, ligaments, subcutaneous) | max_tumor_bulk_site	C171435 || C173263 || C177625 || C188396 || C70729 || C83315	biospecimen_anatomic_site || sites_of_involvement || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site || biospecimen_type
C	C177537	GDC Value Terminology	C12505	Buccal Mucosa	The mucosal membranes located on the inside of the cheek, in the buccal cavity.	Buccal Mucosa | biospecimen_anatomic_site || Buccal Mucosa | biospecimen_type || Buccal Mucosa | treatment_anatomic_site || Buccal mucosa | sites_of_involvement || Cheek mucosa | progression_or_recurrence_anatomic_site || Cheek mucosa | site_of_resection_or_biopsy || Cheek mucosa | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729 || C83315	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site || biospecimen_type
C	C177537	GDC Value Terminology	C12664	Abdomen	The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.	Abdomen | biospecimen_anatomic_site || Abdomen | metastasis_at_diagnosis_site || Abdomen | sites_of_involvement || Abdomen, NOS | progression_or_recurrence_anatomic_site || Abdomen, NOS | site_of_resection_or_biopsy || Abdomen, NOS | tissue_or_organ_of_origin || Abdomen, total | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12666	Adrenal Gland	A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).	Adrenal | biospecimen_anatomic_site || Adrenal | max_tumor_bulk_site || Adrenal | treatment_anatomic_site || Adrenal Gland | metastasis_at_diagnosis_site || Adrenal gland | primary_site || Adrenal gland, NOS | progression_or_recurrence_anatomic_site || Adrenal gland, NOS | site_of_resection_or_biopsy || Adrenal gland, NOS | sites_of_involvement || Adrenal gland, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12683	Bronchus	Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).	Bronchus | biospecimen_anatomic_site || Bronchus | metastasis_at_diagnosis_site || Bronchus | sites_of_involvement || Bronchus | treatment_anatomic_site	C171435 || C173263 || C177625 || C70729	biospecimen_anatomic_site || sites_of_involvement || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12692	Cerebrospinal Fluid	The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.	Cerebrospinal Fluid | biospecimen_anatomic_site || Cerebrospinal Fluid | biospecimen_type || Cerebrospinal Fluid | metastasis_at_diagnosis_site || Cerebrospinal Fluid | treatment_anatomic_site || Cerebrospinal fluid | sites_of_involvement	C171435 || C173263 || C177625 || C70729 || C83315	biospecimen_anatomic_site || sites_of_involvement || metastasis_at_diagnosis_site || treatment_anatomic_site || biospecimen_type
C	C177537	GDC Value Terminology	C12702	Diaphragm	Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.	Diaphragm | biospecimen_anatomic_site || Diaphragm | sites_of_involvement || Diaphragm | treatment_anatomic_site	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12726	Inguinal Region	The lower region of the anterior abdominal wall located laterally to the pubic region.	Groin | biospecimen_anatomic_site || Groin | metastasis_at_diagnosis_site || Groin | treatment_anatomic_site || Inguinal | max_tumor_bulk_site	C171435 || C177625 || C188396 || C70729	biospecimen_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12727	Heart	A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood).	Heart | biospecimen_anatomic_site || Heart | metastasis_at_diagnosis_site || Heart | progression_or_recurrence_anatomic_site || Heart | site_of_resection_or_biopsy || Heart | sites_of_involvement || Heart | tissue_or_organ_of_origin || Heart | treatment_anatomic_site	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12745	Lymph Node	A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.	Lymph Node | biospecimen_anatomic_site || Lymph Node | treatment_anatomic_site || Lymph Node, NOS | metastasis_at_diagnosis_site || Lymph node, NOS | progression_or_recurrence_anatomic_site || Lymph node, NOS | site_of_resection_or_biopsy || Lymph node, NOS | sites_of_involvement || Lymph node, NOS | tissue_or_organ_of_origin || Lymph nodes | primary_site	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12762	Oropharynx	The part of the pharynx between the soft palate and the upper portion of the epiglottis.	Oropharynx | biospecimen_anatomic_site || Oropharynx | max_tumor_bulk_site || Oropharynx | primary_site || Oropharynx | sites_of_involvement || Oropharynx | treatment_anatomic_site || Oropharynx, NOS | progression_or_recurrence_anatomic_site || Oropharynx, NOS | site_of_resection_or_biopsy || Oropharynx, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12767	Pelvis	The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.	Pelvis | biospecimen_anatomic_site || Pelvis | metastasis_at_diagnosis_site || Pelvis | sites_of_involvement || Pelvis | treatment_anatomic_site || Pelvis, NOS | progression_or_recurrence_anatomic_site || Pelvis, NOS | site_of_resection_or_biopsy || Pelvis, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12770	Peritoneum	The tissue that lines the wall of the abdominal cavity, intestine, mesentery, and pelvic organs. It consists of the parietal peritoneum and the visceral peritoneum.	Peritoneum | biospecimen_anatomic_site || Peritoneum | metastasis_at_diagnosis_site || Peritoneum | treatment_anatomic_site || Peritoneum, NOS | progression_or_recurrence_anatomic_site || Peritoneum, NOS | site_of_resection_or_biopsy || Peritoneum, NOS | sites_of_involvement || Peritoneum, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C177625 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12802	Tonsil	The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.	Tonsil | biospecimen_anatomic_site || Tonsil | primary_site || Tonsil | sites_of_involvement || Tonsil | treatment_anatomic_site	C158874 || C171435 || C173263 || C70729	primary_site || biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C128266	Enitociclib	An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, enitociclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.	PTEF-b/CDK9 Inhibitor BAY1251152 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12903	Supraclavicular Lymph Node	A lymph node which is located above the clavicle.	Lymph Node(s) Supraclavicular | biospecimen_anatomic_site || Lymph Node(s) Supraclavicular | treatment_anatomic_site || Supraclavicular | lymph_node_involved_site || Supraclavicular lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12904	Axillary Lymph Node	One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.	Axillary | lymph_node_involved_site || Axillary lymph nodes | max_tumor_bulk_site || Lymph Node(s) Axilla | biospecimen_anatomic_site || Lymph Node(s) Axilla | treatment_anatomic_site || Lymph Node, Axillary | metastasis_at_diagnosis_site || Lymph nodes of axilla or arm | progression_or_recurrence_anatomic_site || Lymph nodes of axilla or arm | site_of_resection_or_biopsy || Lymph nodes of axilla or arm | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C177570 || C177625 || C188396 || C33027 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || progression_or_recurrence_anatomic_site || metastasis_at_diagnosis_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C12933	Vertebra	Any of the ring-shaped bony structures that constitute the spinal column and surround the spinal cord.	Vertebra | biospecimen_anatomic_site || Vertebra | treatment_anatomic_site || Vertebrae | sites_of_involvement	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C129580	Chk1 Inhibitor SRA737	An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor SRA737 selectively binds to chk1, thereby preventing chk1 activity and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. SRA737 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an adenosine triphosphate (ATP)-dependent serine/threonine kinase overexpressed in a variety of cancer cell types, mediates cell cycle checkpoint control and is essential for DNA repair; it plays a key role in resistance to chemotherapeutic agents by repairing DNA damage.	Chk1 Inhibitor CCT245737 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C129689	Palupiprant	An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.	Prostaglandin E2 EP4 Receptor Inhibitor AN0025 | therapeutic_agents || Prostaglandin E2 EP4 Receptor Inhibitor E7046 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12971	Breast	One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.	Breast | biospecimen_anatomic_site || Breast | max_tumor_bulk_site || Breast | primary_site || Breast | treatment_anatomic_site || Breast, NOS | progression_or_recurrence_anatomic_site || Breast, NOS | site_of_resection_or_biopsy || Breast, NOS | sites_of_involvement || Breast, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C188396 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C13005	Pericardium	A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.	Pericardium | biospecimen_anatomic_site || Pericardium | max_tumor_bulk_site || Pericardium | sites_of_involvement || Pericardium | treatment_anatomic_site	C171435 || C173263 || C188396 || C70729	biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C13063	Neck	The region that connects the head to the rest of the body.	Neck | biospecimen_anatomic_site || Neck | max_tumor_bulk_site || Neck | metastasis_at_diagnosis_site || Neck | sites_of_involvement || Neck | treatment_anatomic_site	C171435 || C173263 || C177625 || C188396 || C70729	biospecimen_anatomic_site || sites_of_involvement || metastasis_at_diagnosis_site || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C13204	Human Chromosome 1	The designation for each member of the largest human autosomal chromosome pair. Chromosome 1 spans about 247 million nucleotide base pairs and represents about 8% of the total DNA in normal diploid cells.	chr1 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13205	Human Chromosome 10	The designation for each member of the tenth largest human autosomal chromosome pair. Chromosome 10 spans about 135 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.	chr10 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13206	Human Chromosome 11	The designation for each member of the eleventh largest human autosomal chromosome pair. Chromosome 11 spans about 134.5 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.	chr11 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13207	Human Chromosome 12	The designation for each member of the twelfth largest human autosomal chromosome pair. Chromosome 12 spans about 143 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.	chr12 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13208	Human Chromosome 13	The designation for each member of the thirteenth largest human autosomal chromosome pair. Chromosome 13 spans about 113 million base pairs and represents between 3.5 and 4% of the total DNA in normal diploid cells.	chr13 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13209	Human Chromosome 14	The designation for each member of the fourteenth largest human autosomal chromosome pair. Chromosome 14 spans about 105 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.	chr14 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13210	Human Chromosome 15	The designation for each member of the fifteenth largest human autosomal chromosome pair. Chromosome 15 spans about 106 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.	chr15 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13211	Human Chromosome 16	The designation for each member of the sixteenth largest human autosomal chromosome pair. Chromosome 16 spans about 90 million base pairs and represents just under 3% of the total DNA in normal diploid cells.	chr16 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13212	Human Chromosome 17	The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.	chr17 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13213	Human Chromosome 18	The designation for each member of the eighteenth largest human autosomal chromosome pair. Chromosome 18 spans about 76 million base pairs and represents about 2.5% of the total DNA in normal diploid cells.	chr18 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13214	Human Chromosome 19	The designation for each member of the nineteenth largest human autosomal chromosome pair. Chromosome 19 spans more than 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.	chr19 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13215	Human Chromosome 2	The designation for each member of the second largest human autosomal chromosome pair. Chromosome 2 spans more than 237 million base pairs and represents almost 8% of the total DNA in normal diploid cells.	chr2 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13216	Human Chromosome 20	The designation for each member of the third smallest human autosomal chromosome pair. Chromosome 20 spans around 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.	chr20 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13217	Human Chromosome 21	The designation for each member of the second smallest human autosomal chromosome pair. Chromosome 21 spans around 47 million nucleotides and represents about 1.5% of the total DNA in normal diploid cells.	chr21 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13218	Human Chromosome 22	The designation for each member of the smallest human autosomal chromosome pair. Chromosome 22 spans about 49 million base pairs and represents between 1.5 and 2% of the total DNA in normal diploid cells.	chr22 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13219	Human Chromosome 3	The designation for each member of the third largest human autosomal chromosome pair. Chromosome 3 spans almost 200 million base pairs and represents about 6.5% of the total DNA in normal diploid cells.	chr3 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13220	Human Chromosome 4	The designation for each member of the fourth largest human autosomal chromosome pair. Chromosome 4 spans more than 186 million base pairs and represents between 6 and 6.5% of the total DNA in normal diploid cells.	chr4 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13221	Human Chromosome 5	The designation for each member of the fifth largest human autosomal chromosome pair. Chromosome 5 spans about 181 million base pairs and represents almost 6% of the total DNA in normal diploid cells.	chr5 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13222	Human Chromosome 6	The designation for each member of the sixth largest human autosomal chromosome pair. Chromosome 6 spans more than 170 million base pairs and represents between 5.5 and 6% of the total DNA in normal diploid cells.	chr6 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13223	Human Chromosome 7	The designation for each member of the seventh largest human autosomal chromosome pair. Chromosome 7 spans more than 158 million base pairs and represents between 5 and 5.5% of the total DNA in normal diploid cells.	chr7 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13224	Human Chromosome 8	The designation for each member of the eighth largest human autosomal chromosome pair. Chromosome 8 spans about 145 million base pairs and represents between 4.5 and 5.0% of the total DNA in normal diploid cells.	chr8 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13225	Human Chromosome 9	The designation for each member of the ninth largest human autosomal chromosome pair. Chromosome 9 spans about 145 million base pairs of nucleic acids and represents between 4 and 4.5% of the total DNA in normal diploid cells.	chr9 | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13285	Human Chromosome X	The sex chromosome that is present in both sexes: singly in males and doubly in females.	chrX | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C13286	Human Chromosome Y	The y-shaped sex chromosome. In mammals, its presence or absence determines male or female sex.	chrY | chromosome	C13202	chromosome
C	C177537	GDC Value Terminology	C136485	Stage IA3	A stage term referring to invasive lung cancer. It includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)	Stage IA3 | ajcc_clinical_stage || Stage IA3 | ajcc_pathologic_stage || Stage IA3 | uicc_clinical_stage || Stage IA3 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C137676	Stage IIID	Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIID depends on the particular type of cancer that it refers to; for example, for cutaneous melanoma, stage IIID is defined as follows: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (partially adapted from AJCC 8th ed.)	Stage IIID | ajcc_clinical_stage || Stage IIID | ajcc_pathologic_stage || Stage IIID | uicc_pathologic_stage	C177555 || C177556 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C137992	Gleason Grade Group 1	Gleason grade defined by Gleason score less than or equal to 6. (ISUP, 2014)	Group 1 | gleason_grade_group	C142346	gleason_grade_group
C	C177537	GDC Value Terminology	C137993	Gleason Grade Group 2	Gleason grade defined by Gleason score 3+4=7. (ISUP, 2014)	Group 2 | gleason_grade_group	C142346	gleason_grade_group
C	C177537	GDC Value Terminology	C137994	Gleason Grade Group 3	Gleason grade defined by Gleason score 4+3=7. (ISUP, 2014)	Group 3 | gleason_grade_group	C142346	gleason_grade_group
C	C177537	GDC Value Terminology	C137995	Gleason Grade Group 4	Gleason grade defined by Gleason score 4+4=8, Gleason score 3+5=8, or Gleason score 5+3=8. (ISUP, 2014)	Group 4 | gleason_grade_group	C142346	gleason_grade_group
C	C177537	GDC Value Terminology	C137996	Gleason Grade Group 5	Gleason grade defined by Gleason score 9-10. (ISUP, 2014)	Group 5 | gleason_grade_group	C142346	gleason_grade_group
C	C177537	GDC Value Terminology	C139414	Breast Cancer pTis (DCIS) TNM Finding v8	Breast cancer with a finding of ductal carcinoma in situ. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)	Tis (DCIS) | ajcc_pathologic_t || Tis (DCIS) | uicc_clinical_t || Tis (DCIS) | uicc_pathologic_t || Tis (DCIS) | ajcc_clinical_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C139415	Breast Cancer pTis (Paget) TNM Finding v8	Paget disease of the nipple not associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. (from AJCC 8th Ed.)	Tis (Paget's) | ajcc_pathologic_t || Tis (Paget's) | uicc_pathologic_t	C177636 || C188448	ajcc_pathologic_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C139980	Stage IIIA1	A stage term that applies to ovarian and fallopian tube carcinoma and indicates that the tumor is limited to ovaries (one or both) or fallopian tube(s) or the tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim. There are positive retroperitoneal lymph nodes only (histologically confirmed) and no distant metastasis. (adapted from AJCC 8th Ed.)	Stage IIIA1 | ajcc_pathologic_stage || Stage IIIA1 | uicc_pathologic_stage	C177556 || C188446	ajcc_pathologic_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C139981	Stage IIIA2	A stage term that applies to ovarian and fallopian tube carcinoma and indicates the presence of microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. There is no distant metastasis. (adapted from AJCC 8th Ed.)	Stage IIIA2 | ajcc_pathologic_stage || Stage IIIA2 | uicc_pathologic_stage	C177556 || C188446	ajcc_pathologic_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C142320	Splenic Lymph Node	Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.	Lymph Node(s) Splenic | biospecimen_anatomic_site || Lymph Node(s) Splenic | treatment_anatomic_site || Splenic | lymph_node_involved_site || Splenic lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C142827	Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion	A sarcoma that arises from the lung. It is related to a bronchus and is often predominantly endobronchial. It is characterized by the proliferation of round and spindle cells within a myxoid stroma. It is associated with the presence of an EWSR1::CREB1 fusion gene.	Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C14338	Human Papillomavirus-16	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-16 (HPV16) has been directly linked to cervical cancer and is significantly associated with invasiveness. Progression from low- to high-grade neoplasia is often associated with the integration of the HPV16 genome into the host chromosome.	HPV16 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C14377	Human Papillomavirus-18	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-18 (HPV18) has been directly linked to cervical cancer and plays a role in the pathogenesis of the disease. The virus integrates its DNA at specific chromosomal locations, such as 8q24 and 12q15. The use of molecular markers for HPV18 infection may allow the identification of patients with early stage cervical cancer and those at high risk for disease recurrence.	HPV18 | hpv_strain	C157110	hpv_strain
C	C177537	GDC Value Terminology	C1476	Denileukin Diftitox	A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.	Denileukin Diftitox | therapeutic_agents || Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C148411	T2d Stage Finding	A TNM stage finding term that refers to choroidal and ciliary body melanoma or conjunctival melanoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)	T2d | ajcc_clinical_t || T2d | ajcc_pathologic_t || T2d | uicc_clinical_t || T2d | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C148412	T3d Stage Finding	A TNM stage finding term that refers to choroidal and ciliary body melanoma, conjunctival melanoma, or retinoblastoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. For retinoblastoma it means hyphema and/or massive vitreous hemorrhage (clinical) or full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels (pathologic). (from AJCC 8th Ed.)	T3d | ajcc_clinical_t || T3d | ajcc_pathologic_t || T3d | uicc_clinical_t || T3d | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C154279	Iruplinalkib	An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, iruplinalkib binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	ALK Inhibitor WX-0593 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C154494	Renal Cell Carcinoma with MiT Translocations	A renal cell carcinoma usually seen in children or young adults. It is characterized by papillary, alveolar and nested growth patterns with clear and eosinophilic cells. The carcinomas range from microscopic lesions to clinically symptomatic tumors. It is associated with translocations/gene fusions involving members of the MiT family of transcription factors. There are two subtypes: TFE3-rearranged renal cell carcinoma [Xp11 translocation renal cell carcinoma] and TFEB-rearranged renal cell carcinoma [t(6;11) renal cell carcinoma].	MiT family translocation renal cell carcinoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C155738	Histone H3.Y	Histone H3.Y (136 aa, ~15 kDa) is encoded by the human H3.Y gene. This protein may be involved in both the positive regulation of transcription and the formation of higher order chromatin structures.	H3.Y | histone_variant	C177620	histone_variant
C	C177537	GDC Value Terminology	C155931	Betifisolimab	A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.	Anti-PD-L1 Monoclonal Antibody MSB2311 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157501	Anzurstobart	An immunoglobulin G1 (IgG1) monoclonal antibody targeting signal-regulatory protein alpha (SIRPa; CD172a) with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anzurstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47/SIRPa-mediated signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Anti-SIRPa Monoclonal Antibody CC-95251 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158067	Luveltamab Tazevibulin	An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.	Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158505	Lorigerlimab	A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.	Anti-PD-1/Anti-CTLA4 DART Protein MGD019 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160147	Safimaltib	An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, safimaltib targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.	MALT1 Inhibitor JNJ-67856633 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160257	Amredobresib	An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.	BET inhibitor BI 894999 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160605	Reozalimab	A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C161831	Autologous PRAME-targeting TCR-engineered T-cells IMA203	A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T-cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.	Autologous TCR-engineered T-cells IMA203 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162537	Lorukafusp alfa	A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.	Hu14.18-IL2 Fusion Protein EMD 273063 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162676	Elzovantinib	An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.	Multi-kinase Inhibitor TPX-0022 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C164004	Mediastinal Soft Tissue	Any non-hardened or non-calcified tissue found in the mediastinum.	Mediastinal Soft Tissue | biospecimen_anatomic_site || Mediastinal Soft Tissue | treatment_anatomic_site || Mediastinal soft tissue | max_tumor_bulk_site || Mediastinal soft tissue | sites_of_involvement	C171435 || C173263 || C188396 || C70729	biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C164006	Nasal Soft Tissue	Any non-hardened or non-calcified tissue found in the nose.	Nasal Soft Tissue | biospecimen_anatomic_site || Nasal Soft Tissue | treatment_anatomic_site || Nasal soft tissue | sites_of_involvement	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C164007	Periorbital Soft Tissue	Any non-hardened or non-calcified tissue found in the periorbital area.	Peri-orbital soft tissue | max_tumor_bulk_site || Peri-orbital soft tissue | sites_of_involvement || Periorbital Soft Tissue | biospecimen_anatomic_site || Periorbital Soft Tissue | treatment_anatomic_site	C171435 || C173263 || C188396 || C70729	biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C164057	Smoke Exposure	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.	Smoke | exposure_type || Smoke exposure, NOS | type_of_smoke_exposure	C157103 || C164057	exposure_type || type_of_smoke_exposure
C	C177537	GDC Value Terminology	C164255	Mixed Neuroendocrine Non-Neuroendocrine Neoplasm	A rare neoplasm that consists of neuroendocrine and non-neuroendocrine cellular components. At least 30% of either component should be present for the diagnosis to be made.	8154/3 | morphology	C176985	morphology
C	C177537	GDC Value Terminology	C165567	Zipalertinib	An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), with potential antineoplastic activity. CLN-081 is also active against other EGFR mutations including exon 19 deletions (exon19del), L858R, and T790M, as well as the less common G719X, L861Q and S768I mutations. Upon administration, zipalertinib specifically and covalently binds to and inhibits a variety of EGFR mutations, with particularly high selectivity against EGFR Ex20ins, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CLN-081 may have therapeutic benefits in tumors with EGFR Ex20ins, as most EGFR mutant-selective inhibitors are not active against EGFR Ex20ins. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Pan-mutation-selective EGFR Inhibitor CLN-081 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C165588	Vepsitamab	A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration vepsitamab binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.	Anti-MUC17/CD3 BiTE Antibody AMG 199 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C165776	Revumenib	An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.	Menin-MLL Interaction Inhibitor SNDX-5613 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C167206	Dalutrafusp Alfa	A bispecific antibody that simultaneously binds two different as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, dalutrafusp alfa targets and binds the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.	Bispecific Antibody GS-1423 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C167347	Tulmimetostat	An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, tulmimetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.	EZH2 inhibitor CPI-0209 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C168604	Tecaginlimab	A humanized immunoglobulin (Ig) G1, Fc-silenced, bispecific, agonistic monoclonal antibody targeting both CD40 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration,  tecaginlimab simultaneously binds to CD40 and 4-1BB, crosslinks CD40 and 4-1BB positive cells, induces conditional stimulation, and activates both CD40- and 4-1BB-medicated signaling. The activation of CD40-mediated signaling triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The activation of 4-1BB-mediated signaling induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system. 4-1BB, a surface glycoprotein of the TNFRSF, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C168996	Thorium Th 227 Trastuzumab Corixetan	A radioimmunoconjugate consisting of trastuzumab, a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 trastuzumab corixetan, the trastuzumab moiety targets and specifically binds to HER2 on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.	Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C170516	Nanrilkefusp Alfa	A human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra), with potential antineoplastic activities. Upon administration, nanrilkefusp alfa activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. Nanrilkefusp alfa is more potent than unmodified IL-15 and does not require endogenous IL-15Ra for its action.	Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C170907	Rilunermin Alfa	A recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L), with potential pro-apoptotic and antineoplastic activities. The binding of TRAIL to the Trimer-Tag allows TRAIL to form a stable covalently-linked homotrimer. Upon administration rilunermin alfa targets, binds to and trimerizes the TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby activating caspases and inducing apoptosis in TRAIL-R1/R2-expressing tumor cells. TRAIL, a homotrimeric type II transmembrane protein and member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types; The induction of receptor trimerization is needed for the initiation of the apoptotic signaling pathway. The TRAIL-Trimer retains similar bioactivity and receptor binding kinetics as native TRAIL but has more favorable pharmacokinetics and antitumor activity than native TRAIL.	Recombinant Human TRAIL-Trimer Fusion Protein SCB-313 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C171152	Single Cell RNA Sequencing	A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an amplified nucleotide sample that was derived from a single cell.	scRNA-Seq | experimental_strategy || scRNA-Seq | library_strategy	C177618 || C43622	library_strategy || experimental_strategy
C	C177537	GDC Value Terminology	C171577	Ifinatamab Deruxtecan	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.	Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C171937	Volrustomig	An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. In addition, volrustomig is internalized and is able to degrade PD-1. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with volrustomig may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. It may also decrease toxicity by avoiding the binding to CTLA-4-expressing T-cells that are devoid of PD-1. The engineered Fc domain may reduce Fc effector function.	Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172194	Acasunlimab	A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, acasunlimab simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, acasunlimab acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, acasunlimab prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172396	Golcadomide	A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, golcadomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.	Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C172443	Ivicentamab	An Fc-engineered, humanized, bispecific hexamer formation-enhanced immunoglobulin (Ig) G1 monoclonal antibody that targets two separate epitopes on the tumor-associated antigen (TAA) CD37, with the E430G hexamerization-enhancing mutation, with potential immunomodulating and antineoplastic activities. Upon administration, ivicentamab specifically targets and binds to two non-overlapping CD37 epitopes, thereby inducing an assembly of antibody hexamers through intermolecular Fc-Fc interactions at the cell surface of CD37-overexpressing tumor cells. These hexamers recruit and activate C1, the first component of complement, thereby triggering the complement cascade which activates the immune system to induce complement-dependent cytotoxicity (CDC). In addition, the binding of ivicentamab to the CD37-overexpressing tumor cells also causes antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. The E430G mutation in the Fc domains enhances Fc-mediated IgG hexamerization upon cellular target binding, and enhances CDC.	Anti-CD37 Bispecific Monoclonal Antibody GEN3009 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173437	Tunlametinib	An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, tunlametinib selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.	MEK Inhibitor HL-085 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173726	Osemitamab	A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, osemitamab specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation.  CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. Osemitamab is produced with reduced fucosylation.	Anti-Claudin18.2 Monoclonal Antibody TST001 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174010	Pertuzumab Zuvotolimod	An immunotherapeutic composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a Toll-like receptor 8 (TLR8; CD288) agonist, with potential immunostimulating and antineoplastic activities. Upon intravenous administration pertuzumab zuvotolimod, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells, thereby localizing the TLR8 agonist directly to the tumor site. In turn, the TLR8 agonist moiety binds to TLR8 expressed on myeloid cells within the tumor microenvironment (TME). This activates myeloid cells, including tumor-associated macrophages (TAMs), myeloid cell-derived suppressive cells (MDSCs), and conventional dendritic cells (cDCs). This may lead to the activation of nuclear factor NF-kappa-B, the production of pro-inflammatory cytokines and chemokines, macrophage-induced tumor cell killing, inflammasome activation, activation of cytolytic natural killer (NK) cells and neutrophils, and the induction of a Th1-weighted anti-tumor immune response. It also reverses the suppression of senescent naive and tumor-specific T-cells, and enhances the anti-tumor cytotoxic T-lymphocyte (CTL) immune response. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	HER2-directed TLR8 Agonist SBT6050 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174050	Briquilimab	A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs). Upon administration, briquilimab targets and binds to CD117. This prevents the binding of stem cell factor (SCF) to its receptor CD117 on HSCs.  As CD117 binding to SCF is critical for survival and maintenance of blood forming stem cells, blocking this interaction causes the HSCs that are present in the bone marrow niches to be depleted. Briquilimab can potentially be used as a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.	Anti-CD117 Monoclonal Antibody JSP191 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174140	Latikafusp	An antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-21 (IL-21), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of latikafusp, the antibody moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-21 mutein moiety binds to the IL-21 receptor and activates IL-21 cytokine signaling in PD-1-expressing cells. This may modulate the proliferation and/or differentiation, promote survival, and increase the cytolytic activity of PD-1-expressing T-cells, thereby enhancing T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-21 plays an important role in the regulation of cellular immune responses.	Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174206	Camonsertib	An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, camonsertib selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.	ATR Inhibitor RP-3500 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174515	Davoceticept	A fusion protein composed of the N-terminal Ig variable-like (IgV) domain of CD80 fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration, davoceticept targets and binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) expressed on tumor cells, which blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279), and leads to PD-L1-dependent CD28 binding and co-stimulation in the local tumor microenvironment (TME). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling, leads to the co-stimulation of T-cell responses including the activation of na?ve and memory T-cells in the TME and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, davoceticept targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4) expressed on T-cells. This prevents the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation. This further promotes T-cell activity. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells (APCs) that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.	CD80-Fc Fusion Protein ALPN-202 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C17649	Other	Different than the one(s) previously specified or mentioned.	Other | additional_pathology_findings || Other | alcohol_type || Other | ann_arbor_b_symptoms_described || Other | biospecimen_anatomic_site || Other | comorbidity || Other | diabetes_treatment_type || Other | dysplasia_type || Other | embolic_agent || Other | immunosuppressive_treatment_type || Other | instrument_model || Other | library_selection || Other | max_tumor_bulk_site || Other | method_of_diagnosis || Other | method_of_sample_procurement || Other | molecular_analysis_method || Other | platform || Other | reason_treatment_ended || Other | relationship_type || Other | sites_of_involvement || Other | therapeutic_agents || Other | treatment_anatomic_site || Other | treatment_type || Other | type_of_tobacco_used || Other | variant_type || other | classification_of_tumor || other | race	C158809 || C16457 || C166276 || C17049 || C171435 || C173263 || C173544 || C174459 || C177576 || C177610 || C177629 || C18685 || C188396 || C1909 || C19770 || C25218 || C4086 || C43283 || C45378 || C45902 || C574 || C70700 || C70729 || C83393 || C97229 || C99532	additional_pathology_findings || comorbidity || reason_treatment_ended || race || biospecimen_anatomic_site || sites_of_involvement || variant_type || classification_of_tumor || method_of_diagnosis || instrument_model || type_of_tobacco_used || library_selection || max_tumor_bulk_site || therapeutic_agents || molecular_analysis_method || treatment_type || dysplasia_type || ann_arbor_b_symptoms_described || platform || alcohol_type || immunosuppressive_treatment_type || method_of_sample_procurement || treatment_anatomic_site || relationship_type || embolic_agent || diabetes_treatment_type
C	C177537	GDC Value Terminology	C17998	Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	Unknown | adapter_content || Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_staging_system_edition || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | barretts_esophagus_goblet_cells_present || Unknown | basic_statistics || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosome || Unknown | classification_of_tumor || Unknown | coal_dust_exposure || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidity || Unknown | comorbidity_method_of_diagnosis || Unknown | composition || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | eln_risk_classification || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | environmental_tobacco_smoke_exposure || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | exposure_duration || Unknown | exposure_source || Unknown | figo_stage || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histone_family || Unknown | histone_variant || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormone_replacement_therapy_type || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_result || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | kmer_content || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | medulloblastoma_molecular_classification || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | metastasis_at_diagnosis_site || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | morphology || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | normal_tumor_genotype_snp_match || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | overrepresented_sequences || Unknown | per_base_n_content || Unknown | per_base_sequence_content || Unknown | per_base_sequence_quality || Unknown | per_sequence_gc_content || Unknown | per_sequence_quality_score || Unknown | per_tile_sequence_quality || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | ploidy || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | preservation_method || Unknown | primary_diagnosis || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | race || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | residual_disease || Unknown | risk_factor || Unknown | risk_factor_treatment || Unknown | sample_type || Unknown | satellite_nodule_present || Unknown | second_gene_symbol || Unknown | secondhand_smoke_as_child || Unknown | sequence_duplication_levels || Unknown | sequence_length_distribution || Unknown | site_of_resection_or_biopsy || Unknown | sites_of_involvement || Unknown | smoking_frequency || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | test_units || Unknown | therapeutic_agents || Unknown | time_between_waking_and_first_smoke || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_site || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_regression_grade || Unknown | type_of_smoke_exposure || Unknown | uicc_clinical_m || Unknown | uicc_clinical_n || Unknown | uicc_clinical_stage || Unknown | uicc_clinical_t || Unknown | uicc_pathologic_m || Unknown | uicc_pathologic_n || Unknown | uicc_pathologic_stage || Unknown | uicc_pathologic_t || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serologies || Unknown | vital_status || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status	C102562 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C15256 || C15599 || C156421 || C156422 || C157233 || C157410 || C157425 || C158874 || C159824 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C16515 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177574 || C177576 || C177578 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177597 || C177598 || C177599 || C177600 || C177601 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177625 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188372 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C35529 || C36037 || C36292 || C38032 || C4086 || C45824 || C45902 || C4809 || C49236 || C50995 || C53414 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || primary_site || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidity || fragmentation_enzyme || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factor || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || coal_dust_exposure || method_of_diagnosis || dysplasia_degree || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || metastasis_at_diagnosis_site || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || exposure_source || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || dysplasia_type || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || composition || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || sample_type || treatment_anatomic_site || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C2570	Arginine Butyrate	A compound composed of the short chain fatty acid (SCFA) butyrate combined with the amino acid arginine, with potential Epstein-Barr virus thymidine kinase gene (EBV-TK)-inducing activity. Upon administration, arginine butyrate induces the expression of thymidine kinase (TK). This activates a co-administered antiviral, such as ganciclovir, and results in the destruction of EBV-infected cancer cells. In addition, butyrate inhibits histone deacetylase (HDAC), which results in hyperacetylation of histones H3 and H4. Acetylated histones have a reduced affinity for chromatin; this reduced histone-chromatin affinity may allow chromosomal unfolding, potentially enhancing the expression of genes related to tumor cell growth arrest and apoptosis.	Short Chain Fatty Acid HQK-1004 | therapeutic_agents || Arginine Butyrate | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C26470	Maxilla	The upper jawbone in vertebrates; it is fused to the cranium.	Maxilla | biospecimen_anatomic_site || Maxilla | max_tumor_bulk_site || Maxilla | sites_of_involvement || Maxilla | treatment_anatomic_site	C171435 || C173263 || C188396 || C70729	biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C27031	Pancreatic Neuroendocrine Neoplasm	A neoplasm with neuroendocrine differentiation that arises from the pancreas.  It includes neuroendocrine tumors and neuroendocrine carcinomas.	8150/1 | morphology || Islet cell tumor, NOS | primary_diagnosis || Pancreatic endocrine tumor, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27252	Enterochromaffin-Like Cell Neuroendocrine Tumor G1	A well differentiated, low grade neuroendocrine neoplasm (carcinoid tumor) arising from the gastrointestinal tract. It is characterized by the presence of enterochromaffin-like type granules in the neoplastic cells.	8242/1 | morphology || 8242/3 | morphology || ECL cell carcinoid, NOS | primary_diagnosis || ECL cell carcinoid, malignant | primary_diagnosis || Enterochromaffin-like cell carcinoid, NOS | primary_diagnosis || Enterochromaffin-like cell tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27720	Pancreatic Neuroendocrine Tumor	A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.	8150/0 | morphology || Pancreatic endocrine tumor, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C27964	Stage 0a	Cancer confined to the epithelium with formation of papillary structures without invasion of the basement membrane or noninvasive localized squamous cell carcinoma.	Stage 0a | ajcc_clinical_stage || Stage 0a | ajcc_pathologic_stage || Stage 0a | uicc_clinical_stage || Stage 0a | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27965	Stage 0is	Cancer confined to the epithelium with formation of a flat surface without invasion of the basement membrane.	Stage 0is | ajcc_clinical_stage || Stage 0is | ajcc_pathologic_stage || Stage 0is | uicc_clinical_stage || Stage 0is | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27966	Stage I	Invasive cancer confined to the original anatomic site of growth without lymph node involvement.	Stage I | ajcc_clinical_stage || Stage I | ajcc_pathologic_stage || Stage I | uicc_clinical_stage || Stage I | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27967	Stage IIA	Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIA is defined as follows: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIA is defined as follows: T1, N0, M0, G3, G4. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)	Stage IIA | ajcc_clinical_stage || Stage IIA | ajcc_pathologic_stage || Stage IIA | uicc_clinical_stage || Stage IIA | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27968	Stage IIB	Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.  The definition of stage IIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIB is defined as follows: (T2, N1, MO); (T3, NO, MO). T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IIB is defined as follows: T2, N0, M0, G3, G4. T2: Tumor more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G3: Poorly differentiated. G4: Undifferentiated. (partially adapted from AJCC 7th ed.)	Stage IIB | ajcc_clinical_stage || Stage IIB | ajcc_pathologic_stage || Stage IIB | uicc_clinical_stage || Stage IIB | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27969	Stage IIC	A cancer stage generally indicating the invasion of adjacent structures by cancer without distant metastases.	Stage IIC | ajcc_clinical_stage || Stage IIC | ajcc_pathologic_stage || Stage IIC | uicc_clinical_stage || Stage IIC | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27970	Stage III	Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.	Stage III | ajcc_clinical_stage || Stage III | ajcc_pathologic_stage || Stage III | uicc_clinical_stage || Stage III | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27971	Stage IV	Cancer that has spread to distant anatomic sites beyond its original site of growth.	Stage IV | ajcc_clinical_stage || Stage IV | ajcc_pathologic_stage || Stage IV | uicc_clinical_stage || Stage IV | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27975	Stage IA	Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IA is defined as follows: T1, N0, M0. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IA is defined as follows: T1, N0, M0, G1, GX. T1: Tumor 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 8th ed.)	Stage IA | ajcc_clinical_stage || Stage IA | ajcc_pathologic_stage || Stage IA | uicc_clinical_stage || Stage IA | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27976	Stage IB	Invasive cancer confined to the original anatomic site of growth without lymph node involvement.  The definition of stage IB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IB is defined as follows: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. N1mi: Nodal micrometastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for bone cancer, stage IB is defined as follows: (T2, N0, M0, G1, G2, GX); (T3, N0, M0, G1, G2, GX). T2: Tumor more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well differentiated-low grade. G2: Moderately differentiated-low grade. GX: Grade cannot be assessed. (partially adapted from AJCC 7th ed.)	Stage IB | ajcc_clinical_stage || Stage IB | ajcc_pathologic_stage || Stage IB | uicc_clinical_stage || Stage IB | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27977	Stage IIIA	Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIIA depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIA is defined as follows: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor 20 mm or less in greatest dimension. T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension. T3: Tumor more than 50 mm in greatest dimension. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIA is defined as follows: T3a, N0, M0. T3a: Tumor involves lower third of vagina, no extension to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)	Stage IIIA | ajcc_clinical_stage || Stage IIIA | ajcc_pathologic_stage || Stage IIIA | uicc_clinical_stage || Stage IIIA | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27978	Stage IIIB	Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIB depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIB is defined as follows: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules). N0: No regional lymph node metastasis. N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s). N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for cervical cancer, stage IIIB is defined as follows: (T3b, Any N, M0); (T1-3, N1, M0). T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)	Stage IIIB | ajcc_clinical_stage || Stage IIIB | ajcc_pathologic_stage || Stage IIIB | uicc_clinical_stage || Stage IIIB | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27979	Stage IVA	Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVA depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVA is defined as follows: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Distant metastasis to lung; for vaginal cancer, stage IVA is defined as follows: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (partially adapted from AJCC 7th ed.)	Stage IVA | ajcc_clinical_stage || Stage IVA | ajcc_pathologic_stage || Stage IVA | uicc_clinical_stage || Stage IVA | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27980	Stage IVB	Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVB depends on the particular type of cancer that it refers to; for example, for bone cancer, stage IVB is defined as follows: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis to other distant sites; for vaginal cancer, stage IVB is defined as follows: Any T, Any N, M1. M1: Distant metastasis. (partially adapted from AJCC 7th ed.)	Stage IVB | ajcc_clinical_stage || Stage IVB | ajcc_pathologic_stage || Stage IVB | uicc_clinical_stage || Stage IVB | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27981	Stage IC	A cancer stage generally indicating the local invasion of tissues by cancer at the primary site.	Stage IC | ajcc_clinical_stage || Stage IC | ajcc_pathologic_stage || Stage IC | uicc_clinical_stage || Stage IC | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27982	Stage IIIC	Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites.  The definition of stage IIIC depends on the particular type of cancer that it refers to; for example, for breast cancer, stage IIIC is defined as follows: Any T, N3, M0. N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. M0: No clinical or radiographic evidence of distant metastasis. M0 includes M0(i+); for appendix carcinoma, stage IIIC is defined as follows: Any T, N2, M0. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (partially adapted from AJCC 7th ed.)	Stage IIIC | ajcc_clinical_stage || Stage IIIC | ajcc_pathologic_stage || Stage IIIC | uicc_clinical_stage || Stage IIIC | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27983	Stage IA1	A stage term referring to invasive cervical and lung cancer.  For cervical cancer, it includes: T1a1, N0, M0.  T1a1: Tumor with stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)	Stage IA1 | ajcc_clinical_stage || Stage IA1 | ajcc_pathologic_stage || Stage IA1 | uicc_clinical_stage || Stage IA1 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C27984	Stage IA2	A stage term referring to invasive cervical cancer and invasive lung cancer. For cervical cancer, it includes: T1a2, N0, M0.  T1a2: Tumor with stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. For lung cancer, it includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)	Stage IA2 | ajcc_clinical_stage || Stage IA2 | ajcc_pathologic_stage || Stage IA2 | uicc_clinical_stage || Stage IA2 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C28051	Stage 0	Cancer confined to the epithelium without invasion of the basement membrane.	Stage 0 | ajcc_clinical_stage || Stage 0 | ajcc_pathologic_stage || Stage 0 | uicc_clinical_stage || Stage 0 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C28052	Stage IB1	A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b1, N0, M0. (partially adapted from AJCC)	Stage IB1 | ajcc_clinical_stage || Stage IB1 | ajcc_pathologic_stage || Stage IB1 | uicc_clinical_stage || Stage IB1 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C28053	Stage IB2	A stage term referring to invasive cervical cancer that is confined to the cervix without lymph node involvement.  It includes: T1b2, N0, M0.  (partially adapted from AJCC)	Stage IB2 | ajcc_clinical_stage || Stage IB2 | ajcc_pathologic_stage || Stage IB2 | uicc_clinical_stage || Stage IB2 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C28054	Stage II	Invasive cancer more extensive than stage I, usually involving local lymph nodes without spread to distant anatomic sites.	Stage II | ajcc_clinical_stage || Stage II | ajcc_pathologic_stage || Stage II | uicc_clinical_stage || Stage II | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C28055	Stage IVC	Cancer that has spread to distant anatomic sites beyond its original site of growth. The definition of stage IVC depends on the particular type of cancer that it refers to; for example, for head and neck carcinomas (lip and oral cavity carcinoma, laryngeal carcinoma, nasal cavity and paranasal sinus carcinoma, pharynx carcinoma, thyroid gland carcinoma, and major salivary gland carcinoma) and head and neck mucosal melanoma, stage IVC is defined as follows: any T, any N, M1; for appendix carcinoma, stage IVC is defined as follows: any T, any N, M1b, any G. M1: Distant metastasis.  M1b: Nonperitoneal metastasis.  G: Grade (cellular differentiation).	Stage IVC | ajcc_clinical_stage || Stage IVC | ajcc_pathologic_stage || Stage IVC | uicc_clinical_stage || Stage IVC | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C28285	Stage Is	Testicular cancer found in the testicle, spermatic cord and scrotum, associated with slightly elevated levels of all tumor markers or moderately/highly elevated levels of one or more tumor markers.	Stage IS | ajcc_clinical_stage || Stage IS | ajcc_pathologic_stage || Stage IS | uicc_clinical_stage || Stage IS | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C2858	Adrenal Cortical Neoplasm	A benign or malignant (primary or metastatic) neoplasm affecting the adrenal cortex.	8370/0 | morphology || Adrenal cortical tumor, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C2862	Primary Myelofibrosis	A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)	9961/3 | morphology || Agnogenic myeloid metaplasia | primary_diagnosis || Megakaryocytic myelosclerosis | primary_diagnosis || Myelofibrosis with myeloid metaplasia | primary_diagnosis || Myelosclerosis with myeloid metaplasia | primary_diagnosis || Primary myelofibrosis | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3070	Granulosa Cell Tumor	A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.	8620/1 | morphology || Granulosa cell tumor, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3105	Von Hippel Lindau Syndrome	An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004	Von Hippel-Lindau Syndrome | risk_factor	C17103	risk_factor
C	C177537	GDC Value Terminology	C32298	Cervical Lymph Node	Any of the lymph nodes located in the neck.	Cervical | lymph_node_involved_site || Cervical lymph nodes | max_tumor_bulk_site || Lymph Node(s) Cervical | biospecimen_anatomic_site || Lymph Node(s) Cervical | treatment_anatomic_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C32979	Leptomeninges	The two innermost layers of tissue that cover the brain and spinal cord, the arachnoid mater and the pia mater.	Leptomeninges | biospecimen_anatomic_site || Leptomeninges | sites_of_involvement || Leptomeninges | treatment_anatomic_site	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C33073	Mediastinal Lymph Node	A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent.	Lymph Node(s) Mediastinal | treatment_anatomic_site || Lymph Nodes(s) Mediastinal | biospecimen_anatomic_site || Mediastinal | lymph_node_involved_site || Mediastinal lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C33103	Mesentery	A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines.	Mesentery | biospecimen_anatomic_site || Mesentery | sites_of_involvement || Mesentery | treatment_anatomic_site	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C33105	Mesothelium	A simple layer of cells, derived from the mesoderm that lines the coelom or body cavity of the embryo. In the adult, it covers all true serous membranes (peritoneum, pericardium, pleura).	Mesothelium | biospecimen_anatomic_site || Mesothelium | sites_of_involvement || Mesothelium | treatment_anatomic_site	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C33209	Omentum	A fold of peritoneum originating at the stomach and supporting the viscera.	Omentum | biospecimen_anatomic_site || Omentum | metastasis_at_diagnosis_site || Omentum | sites_of_involvement || Omentum | treatment_anatomic_site	C171435 || C173263 || C177625 || C70729	biospecimen_anatomic_site || sites_of_involvement || metastasis_at_diagnosis_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C3329	Pituitary Neuroendocrine Tumor	A well-differentiated neuroendocrine neoplasm that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. It has a low frequency of metastatic spread. When metastatic, the term metastatic pituitary neuroendocrine tumor is endorsed instead of pituitary carcinoma. (WHO)	8272/0 | morphology || Pituitary adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C33556	Sinus	A recess, cavity, or channel.	Sinus | biospecimen_anatomic_site || Sinus | sites_of_involvement || Sinus | treatment_anatomic_site	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C3721	Lymphomatoid Papulosis	A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).	9718/3 | morphology || Lymphomatoid papulosis | primary_diagnosis	C16457 || C176985 || C177621	comorbidity || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3809	Neuroendocrine Neoplasm	An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.	Neuroendocrine Tumor | comorbidity	C16457	comorbidity
C	C177537	GDC Value Terminology	C38679	Yttrium Y 90 Glass Microspheres	An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden. (NCI04)	Y-90 Therasphere | embolic_agent || Yttrium Y 90 Glass Microspheres | therapeutic_agents	C1909 || C97229	therapeutic_agents || embolic_agent
C	C177537	GDC Value Terminology	C40345	Testicular Intratubular Germ Cell Neoplasia	A non-invasive lesion of the testis, characterized by the presence of malignant large germ cells with abundant cytoplasm in the seminiferous tubules. It may be associated with undescended or atrophic testis and infertility. The vast majority of cases progress to invasive germ cell tumors.	9064/2 | morphology || Intratubular malignant germ cells | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4163	Adrenal Cortical Compact Cell Adenoma	An adenoma of the adrenal cortex composed of neoplastic compact cells with eosinophilic cytoplasm.	8371/0 | morphology || Adrenal cortical adenoma, compact cell | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4164	Pigmented Adrenal Cortical Adenoma	A usually functioning adenoma of the adrenal cortex. Grossly, it has a dark brown appearance and is characterized by the presence of neoplastic cells containing abundant intracytoplasmic lipofuscin. It may be associated with Cushing syndrome.	8372/0 | morphology || Adrenal cortical adenoma, pigmented | primary_diagnosis || Black adenoma | primary_diagnosis || Pigmented adenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4165	Adrenal Cortical Clear Cell Adenoma	An adenoma of the adrenal cortex composed of neoplastic clear cells containing intracytoplasmic lipid droplets.	8373/0 | morphology || Adrenal cortical adenoma, clear cell | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4166	Adrenal Cortical Glomerulosa Cell Adenoma	An adenoma of the adrenal cortex composed of neoplastic cells with cytologic features of glomerulosa cells.	8374/0 | morphology || Adrenal cortical adenoma, glomerulosa cell | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4167	Adrenal Cortical Mixed Cell Adenoma	An adenoma of the adrenal cortex composed of a mixed neoplastic cellular population, including varying numbers of neoplastic clear and compact cells.	8375/0 | morphology || Adrenal cortical adenoma, mixed cell | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4207	Juvenile Granulosa Cell Tumor	A sex cord-stromal tumor occurring in the ovary and testis. In females it occurs predominantly in the first three decades of life and presents unilaterally as stage I disease in the vast majority of cases. It is characterized by the presence of granulosa cells forming macrofollicular structures. The majority of cases have a good prognosis. In males it represents the most frequent congenital testicular neoplasm, and the vast majority of cases occur in the perinatal period. It presents as a scrotal or abdominal mass, and it more often affects the left testis. Approximately 20% of the patients have ambiguous external genitalia. It is characterized by the presence of cystic spaces lined by granulosa cells and cells resembling theca cells. Metastases have not been reported.	8622/1 | morphology || Granulosa cell tumor, juvenile | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C42576	Kilogram per Cubic Meter	A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.	g/L | test_units || mg/mL | treatment_dose_units	C166199 || C67415	treatment_dose_units || test_units
C	C177537	GDC Value Terminology	C4276	Juvenile Breast Fibroadenoma	A breast fibroadenoma that usually occurs in young women. It is characterized by epithelial hyperplasia and an increased stromal cellularity.	9030/0 | morphology || Juvenile fibroadenoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C43234	Not Reported	Not provided or available.	Not Reported | adapter_content || Not Reported | adrenal_hormone || Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | basic_statistics || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosome || Not Reported | clinical_trial_indicator || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidity || Not Reported | comorbidity_method_of_diagnosis || Not Reported | composition || Not Reported | consistent_pathology_review || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | double_expressor_lymphoma || Not Reported | double_hit_lymphoma || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | eln_risk_classification || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | exposure_duration || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | history_of_tumor || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormone_replacement_therapy_type || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_result || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | kmer_content || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | medulloblastoma_molecular_classification || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | metastasis_at_diagnosis_site || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | morphology || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | normal_tumor_genotype_snp_match || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | overrepresented_sequences || Not Reported | parent_with_radiation_exposure || Not Reported | per_base_n_content || Not Reported | per_base_sequence_content || Not Reported | per_base_sequence_quality || Not Reported | per_sequence_gc_content || Not Reported | per_sequence_quality_score || Not Reported | per_tile_sequence_quality || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | ploidy || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | preservation_method || Not Reported | primary_diagnosis || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | residual_disease || Not Reported | rhabdoid_present || Not Reported | risk_factor || Not Reported | risk_factor_treatment || Not Reported | route_of_administration || Not Reported | sample_type || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | second_gene_symbol || Not Reported | secondhand_smoke_as_child || Not Reported | sequence_duplication_levels || Not Reported | sequence_length_distribution || Not Reported | site_of_resection_or_biopsy || Not Reported | sites_of_involvement || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | test_units || Not Reported | therapeutic_agents || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_site || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_regression_grade || Not Reported | uicc_clinical_m || Not Reported | uicc_clinical_n || Not Reported | uicc_clinical_stage || Not Reported | uicc_clinical_t || Not Reported | uicc_pathologic_m || Not Reported | uicc_pathologic_n || Not Reported | uicc_pathologic_stage || Not Reported | uicc_pathologic_t || Not Reported | undescended_testis_corrected || Not Reported | undescended_testis_corrected_laterality || Not Reported | undescended_testis_corrected_method || Not Reported | undescended_testis_history || Not Reported | undescended_testis_history_laterality || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serologies || Not Reported | vital_status || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status	C102562 || C105721 || C106304 || C106317 || C106541 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127768 || C127772 || C129439 || C13202 || C133427 || C133706 || C138899 || C139007 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C15256 || C15599 || C156421 || C156422 || C157233 || C157410 || C157425 || C157437 || C158874 || C160720 || C160827 || C160996 || C16124 || C161320 || C16165 || C162221 || C16457 || C16564 || C166229 || C16687 || C17001 || C17049 || C17103 || C171253 || C171435 || C173263 || C173544 || C17357 || C173595 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177570 || C177571 || C177572 || C177576 || C177578 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177625 || C177626 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188387 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C25185 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C29878 || C2991 || C33027 || C35529 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C45824 || C45902 || C4809 || C49236 || C50995 || C53414 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C95149 || C99532	inpc_grade || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || hysterectomy_type || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || lymphatic_invasion_present || satellite_nodule_present || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || comorbidity || ethnicity || tumor_descriptor || histone_family || ploidy || race || risk_factor || second_gene_symbol || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || dysplasia_degree || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serologies || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || metastasis_at_diagnosis_site || secondhand_smoke_as_child || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || clinical_trial_indicator || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || laterality || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || relative_with_cancer_history || disease_type || lymph_node_involved_site || lymph_node_involvement || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || zygosity || alcohol_type || residual_disease || treatment_or_therapy || disease_response || composition || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || sample_type || treatment_anatomic_site || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || ishak_fibrosis_score || diabetes_treatment_type
C	C177537	GDC Value Terminology	C43362	Anus	The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.	Anus | biospecimen_anatomic_site || Anus | treatment_anatomic_site || Anus, NOS | progression_or_recurrence_anatomic_site || Anus, NOS | site_of_resection_or_biopsy || Anus, NOS | sites_of_involvement || Anus, NOS | tissue_or_organ_of_origin	C156421 || C156422 || C171435 || C173263 || C177570 || C70729	site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C45202	Low Grade Fibromyxoid Sarcoma	A low-grade, late-metastasizing variant of fibrosarcoma characterized by alternating fibrous and myxoid areas and a whorling growth pattern.  The neoplastic cells have a spindle morphology, and lack hyperchromasia or significant nuclear atypia.  Approximately 40% of cases show the focal presence of collagen rosettes.  A t(7;16)(q33;p11) translocation has been identified in the majority of cases, associated with the presence of FUS-CREB3L2 fusion protein.  Rare cases carry the t(11;16)(p11;p11) translocation which is associated with the presence of the FUS-CREB3L1 fusion protein.	Low-grade fibromyxoid sarcoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C45834	Pancreatic Neuroendocrine Microtumor	A non-functioning pancreatic neuroendocrine tumor measuring less than 0.5 cm in diameter.	Pancreatic endocrine tumor, benign | primary_diagnosis || Pancreatic microadenoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C45837	Non-Functioning Pancreatic Neuroendocrine Tumor	A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the absence of a hormone-related clinical syndrome.	Pancreatic endocrine tumor, nonfunctioning | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C4716	Ectomesenchymoma	An exceedingly rare, aggressive malignant mesenchymal neoplasm characterized by the presence of a sarcomatous component and a ganglionic or a neuroectodermal component.	8921/3 | morphology || Ectomesenchymoma | primary_diagnosis || Rhabdomyosarcoma with ganglionic differentiation | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C47858	Breast Paget Disease without Invasive Carcinoma	Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.	Tis (Paget's) | ajcc_clinical_t || Tis (Paget's) | uicc_clinical_t	C177635 || C188411	ajcc_clinical_t || uicc_clinical_t
C	C177537	GDC Value Terminology	C48699	M0 Stage Finding	A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.	M0 | ajcc_clinical_m || M0 | ajcc_pathologic_m || M0 | uicc_clinical_m || M0 | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C48700	M1 Stage Finding	A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.	M1 | ajcc_clinical_m || M1 | ajcc_pathologic_m || M1 | uicc_clinical_m || M1 | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C48701	M1a Stage Finding	A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.	M1a | ajcc_clinical_m || M1a | ajcc_pathologic_m || M1a | uicc_clinical_m || M1a | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C48702	M1b Stage Finding	A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.	M1b | ajcc_clinical_m || M1b | ajcc_pathologic_m || M1b | uicc_clinical_m || M1b | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C48703	M1c Stage Finding	A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.	M1c | ajcc_clinical_m || M1c | ajcc_pathologic_m || M1c | uicc_clinical_m || M1c | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C48704	MX Stage Finding	A distant metastasis TNM finding indicating that the status of distant metastasis cannot be assessed.	MX | ajcc_clinical_m || MX | ajcc_pathologic_m || MX | uicc_clinical_m || MX | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C48705	N0 Stage Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis.	N0 | ajcc_clinical_n || N0 | ajcc_pathologic_n || N0 | uicc_clinical_n || N0 | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48706	N1 Stage Finding	A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to micrometastases or metastases in 1-3 axillary lymph nodes; for cutaneous melanoma it refers to metastasis in 1 regional lymph node; for colorectal cancer it refers to metastases in 1-3 regional lymph nodes; and for bladder cancer it refers to metastasis in 1 regional lymph node in the true pelvis.	N1 | ajcc_clinical_n || N1 | ajcc_pathologic_n || N1 | uicc_clinical_n || N1 | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48707	N1a Stage Finding	A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in one regional lymph node.	N1a | ajcc_clinical_n || N1a | ajcc_pathologic_n || N1a | uicc_clinical_n || N1a | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48708	N1b Stage Finding	A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for cutaneous melanoma it refers to macrometastasis in one regional lymph node; for colorectal cancer it refers to metastasis in 2-3 regional lymph nodes.	N1b | ajcc_clinical_n || N1b | ajcc_pathologic_n || N1b | uicc_clinical_n || N1b | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48709	N1c Stage Finding	A general term that refers to a TNM finding of cancer metastases usually in a limited number of regional lymph nodes. The definition of N1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 1 to 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for colorectal cancer it refers to tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis.	N1c | ajcc_clinical_n || N1c | ajcc_pathologic_n || N1c | uicc_clinical_n || N1c | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48711	N2a Stage Finding	A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4-6 regional lymph nodes.	N2a | ajcc_clinical_n || N2a | ajcc_pathologic_n || N2a | uicc_clinical_n || N2a | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48712	N2b Stage Finding	A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases; for cutaneous melanoma it refers to macrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in seven or more regional lymph nodes.	N2b | ajcc_clinical_n || N2b | ajcc_pathologic_n || N2b | uicc_clinical_n || N2b | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48713	N2c Stage Finding	A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2c TNM finding depends on the specific type of cancer that it refers to; for example, for cutaneous melanoma it refers to intralymphatic metastases (in transit or satellite metastases) without metastatic nodes; for lip and oral cavity cancer it refers to metastases in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.	N2c | ajcc_clinical_n || N2c | ajcc_pathologic_n || N2c | uicc_clinical_n || N2c | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48714	N3 Stage Finding	A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes; for cutaneous melanoma it refers to metastases in 4 or more regional lymph nodes; for gastric cancer it refers to metastases in 7 or more regional lymph nodes; and for bladder cancer it refers to metastases in common iliac lymph nodes.	N3 | ajcc_clinical_n || N3 | ajcc_pathologic_n || N3 | uicc_clinical_n || N3 | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48715	N3a Stage Finding	A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm) or metastases to the infraclavicular (level III axillary) lymph nodes; for gastric cancer it refers to metastases in 7-15 regional lymph nodes; for nasopharyngeal cancer it refers to metastases to one or more lymph nodes greater than 6 cm in greatest dimension.	N3a | ajcc_clinical_n || N3a | ajcc_pathologic_n || N3a | uicc_clinical_n || N3a | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48716	N3b Stage Finding	A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes, or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected; for gastric cancer it refers to metastases in sixteen or more regional lymph nodes; for nasopharyngeal cancer it refers to extension to the supraclavicular fossa.	N3b | ajcc_clinical_n || N3b | ajcc_pathologic_n || N3b | uicc_clinical_n || N3b | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48717	N3c Stage Finding	A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes.  The definition of N3c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in ipsilateral supraclavicular lymph nodes.	N3c | ajcc_clinical_n || N3c | ajcc_pathologic_n || N3c | uicc_clinical_n || N3c | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48718	NX Stage Finding	A regional lymph node TNM finding indicating that the status of regional lymph nodes cannot be assessed.	NX | ajcc_clinical_n || NX | ajcc_pathologic_n || NX | uicc_clinical_n || NX | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48719	T0 Stage Finding	A primary tumor TNM finding indicating that there is no evidence of primary tumor.	T0 | ajcc_clinical_t || T0 | ajcc_pathologic_t || T0 | uicc_clinical_t || T0 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48720	T1 Stage Finding	A clinical and/or pathologic primary tumor TNM finding indicating that the cancer is limited to the site of growth.	T1 | ajcc_clinical_t || T1 | ajcc_pathologic_t || T1 | uicc_clinical_t || T1 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48721	T1a Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.1cm, but not more than 0.5 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is 4 cm or less in greatest dimension; and for thyroid cancer it refers to a primary tumor that is 1 cm or less in greatest dimension.	T1a | ajcc_clinical_t || T1a | ajcc_pathologic_t || T1a | uicc_clinical_t || T1a | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48722	T1b Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 0.5 cm, but not more than 1.0 cm in greatest dimension; for kidney cancer it refers to a primary tumor that is more than 4 cm, but not more than 7 cm in greatest dimension; and for thyroid cancer it refers to a primary tumor that is more than 1 cm but not more than 2 cm in greatest dimension.	T1b | ajcc_clinical_t || T1b | ajcc_pathologic_t || T1b | uicc_clinical_t || T1b | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48723	T1c Stage Finding	A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.	T1c | ajcc_clinical_t || T1c | ajcc_pathologic_t || T1c | uicc_clinical_t || T1c | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48724	T2 Stage Finding	A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.	T2 | ajcc_clinical_t || T2 | ajcc_pathologic_t || T2 | uicc_clinical_t || T2 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48725	T2a Stage Finding	A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 7 cm but less than or equal to 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the superficial muscularis propria (inner half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is no parametrial invasion.	T2a | ajcc_clinical_t || T2a | ajcc_pathologic_t || T2a | uicc_clinical_t || T2a | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48726	T2b Stage Finding	A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that measures more than 10 cm in greatest dimension, and is limited to the kidney; for bladder cancer it refers to a primary tumor that invades the deep muscularis propria (outer half); for cervical cancer it refers to a primary tumor that invades beyond the uterus but not to the pelvic wall or to the lower third of vagina and there is parametrial invasion.	T2b | ajcc_clinical_t || T2b | ajcc_pathologic_t || T2b | uicc_clinical_t || T2b | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48727	T2c Stage Finding	A general term that refers to a TNM finding of a primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to a primary tumor that involves both lobes of the prostate gland; for ovarian cancer it refers to a primary tumor that involves one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings; for fallopian tube cancer it refers to a primary tumor with pelvic extension and malignant cells in ascites or peritoneal washings.	T2c | ajcc_clinical_t || T2c | ajcc_pathologic_t || T2c | uicc_clinical_t || T2c | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48728	T3 Stage Finding	A clinical and/or pathologic primary tumor TNM finding usually indicating that the cancer is locally invasive, without infiltration of adjacent structures.	T3 | ajcc_clinical_t || T3 | ajcc_pathologic_t || T3 | uicc_clinical_t || T3 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48729	T3a Stage Finding	A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3a TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the renal vein or its segmental (muscle containing) branches or the tumor invades perirenal and/or renal sinus fat but does not extends beyond Gerota's fascia; for cervical cancer it refers to a primary tumor that involves the lower third of vagina, without extension to pelvic wall; for liver cancer it refers to the presence of multiple tumors measuring more than 5 cm in greatest dimension.	T3a | ajcc_clinical_t || T3a | ajcc_pathologic_t || T3a | uicc_clinical_t || T3a | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48730	T3b Stage Finding	A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3b TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava below the diaphragm; for cervical cancer it refers to a primary tumor that extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney; for liver cancer it refers to a single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein.	T3b | ajcc_clinical_t || T3b | ajcc_pathologic_t || T3b | uicc_clinical_t || T3b | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48731	T3c Stage Finding	A general term that refers to a TNM finding of a primary tumor usually indicating that the cancer is locally invasive. The definition of T3c TNM finding depends on the specific type of cancer that it refers to; for example, for kidney cancer it refers to a primary tumor that grossly extends into the vena cava above the diaphragm, or invades the wall of the vena cava; for fallopian tube cancer it refers to a primary tumor with peritoneal metastasis outside the pelvis measuring more than 2 cm in diameter; for melanoma of the conjunctiva it refers to a primary tumor invading the orbit.	T3c | ajcc_clinical_t || T3c | ajcc_pathologic_t || T3c | uicc_clinical_t || T3c | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48732	T4 Stage Finding	A clinical and/or pathologic primary tumor TNM finding indicating direct invasion of adjacent structures by cancer.	T4 | ajcc_clinical_t || T4 | ajcc_pathologic_t || T4 | uicc_clinical_t || T4 | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48733	T4a Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4a TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the prostatic stroma, uterus, and vagina; for gastric cancer it refers to a primary tumor that invades the serosa (visceral peritoneum); for colorectal cancer it refers to a primary tumor that penetrates to the surface of the visceral peritoneum.	T4a | ajcc_clinical_t || T4a | ajcc_pathologic_t || T4a | uicc_clinical_t || T4a | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48734	T4b Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4b TNM finding depends on the specific type of cancer that it refers to; for example, for bladder cancer it refers to a primary tumor that invades the pelvic wall and abdominal wall; for gastric cancer it refers to a primary tumor that invades adjacent structures; for colorectal cancer it refers to a primary tumor with direct invasion or adherence to other organs or structures.	T4b | ajcc_clinical_t || T4b | ajcc_pathologic_t || T4b | uicc_clinical_t || T4b | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48735	T4c Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that extends to the chest wall, not including the pectoralis muscle, and with edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin nodules confined to the same breast; for ocular adnexal lymphoma it refers to a primary tumor that Involves the maxillofacial, ethmoidal, and/or frontal sinuses; for carcinoma of the conjunctiva it refers to a primary tumor that invades adjacent paranasal sinuses.	T4c | ajcc_clinical_t || T4c | ajcc_pathologic_t || T4c | uicc_clinical_t || T4c | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48736	T4d Stage Finding	A general term that refers to a TNM finding of a primary tumor with direct invasion of adjacent structures. The definition of T4d TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that meets the clinical-pathologic criteria of inflammatory carcinoma; for ocular adnexal lymphoma it refers to a primary tumor with intracranial spread; for carcinoma of the conjunctiva it refers to a primary tumor that invades the brain.	T4d | ajcc_clinical_t || T4d | ajcc_pathologic_t || T4d | uicc_clinical_t || T4d | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48737	TX Stage Finding	A primary tumor TNM finding indicating that the status of the primary tumor cannot be assessed.	TX | ajcc_clinical_t || TX | ajcc_pathologic_t || TX | uicc_clinical_t || TX | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48738	Tis Stage Finding	A term that refers to a TNM finding of a primary tumor microscopically defined as carcinoma in situ.	Stage Tis | ajcc_clinical_stage || Stage Tis | ajcc_pathologic_stage || Stage Tis | uicc_clinical_stage || Stage Tis | uicc_pathologic_stage || Tis | ajcc_clinical_t || Tis | ajcc_pathologic_t || Tis | uicc_clinical_t || Tis | uicc_pathologic_t	C177555 || C177556 || C177635 || C177636 || C188409 || C188411 || C188446 || C188448	ajcc_clinical_stage || ajcc_pathologic_stage || ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_stage || uicc_pathologic_t
C	C177537	GDC Value Terminology	C48786	N2 Stage Finding	A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.	N2 | ajcc_clinical_n || N2 | ajcc_pathologic_n || N2 | uicc_clinical_n || N2 | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C48976	Breast Cancer pTis (LCIS) TNM Finding v6 and v7	Breast cancer with a finding of lobular carcinoma in situ. (from AJCC 6th and 7th Ed.)	Tis (LCIS) | ajcc_pathologic_t || Tis (LCIS) | uicc_clinical_t || Tis (LCIS) | uicc_pathologic_t || Tis (LCIS) | ajcc_clinical_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C49024	Low Grade Myofibroblastic Sarcoma	A low-grade malignant neoplasm arising from the soft tissue and rarely bone. It is characterized by the presence of spindle-shaped myofibroblasts and collagenous stroma formation in a storiform growth pattern. Metastasis is very rare.	8825/3 | morphology || Low-grade myofibroblastic sarcoma | primary_diagnosis || Myofibroblastic sarcoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C49027	Sclerosing Epithelioid Fibrosarcoma	A well-circumscribed malignant fibroblastic neoplasm that usually arises from the soft tissue. It is characterized by the presence of nests of malignant epithelioid fibroblasts and sclerotic collagen stroma formation.	Sclerosing epithelioid fibrosarcoma | primary_diagnosis	C177621	primary_diagnosis
C	C177537	GDC Value Terminology	C49487	No	The non-affirmative response to a question.	No | adrenal_hormone || No | alcohol_history || No | anaplasia_present || No | ann_arbor_b_symptoms || No | ann_arbor_extranodal_involvement || No | barretts_esophagus_goblet_cells_present || No | bone_marrow_malignant_cells || No | chemo_concurrent_to_radiation || No | clinical_trial_indicator || No | coal_dust_exposure || No | columnar_mucosa_present || No | consistent_pathology_review || No | diagnosis_pathologically_confirmed || No | double_expressor_lymphoma || No | double_hit_lymphoma || No | environmental_tobacco_smoke_exposure || No | esophageal_columnar_metaplasia_present || No | gastric_esophageal_junction_involvement || No | goblet_cells_columnar_mucosa_present || No | haart_treatment_indicator || No | hepatitis_sustained_virological_response || No | history_of_tumor || No | lost_to_followup || No | lymphatic_invasion_present || No | metaplasia_present || No | mismatch_repair_mutation || No | necrosis_present || No | non_nodal_tumor_deposits || No | normal_tumor_genotype_snp_match || No | parent_with_radiation_exposure || No | perineural_invasion_present || No | pregnant_at_diagnosis || No | premature_at_birth || No | prior_treatment || No | progression_or_recurrence || No | rhabdoid_present || No | risk_factor_treatment || No | sarcomatoid_present || No | secondhand_smoke_as_child || No | synchronous_malignancy || No | treatment_effect_indicator || No | tumor_confined_to_organ_of_origin || No | undescended_testis_corrected || No | undescended_testis_history || No | vascular_invasion_present || no | prior_malignancy || no | progression_or_recurrence || no | relative_with_cancer_history || no | treatment_or_therapy	C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177574 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C29878 || C36037 || C39694 || C49236 || C81229	premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || coal_dust_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || alcohol_history
C	C177537	GDC Value Terminology	C49488	Yes	The affirmative response to a question.	Yes | adrenal_hormone || Yes | alcohol_history || Yes | anaplasia_present || Yes | ann_arbor_b_symptoms || Yes | ann_arbor_extranodal_involvement || Yes | barretts_esophagus_goblet_cells_present || Yes | bone_marrow_malignant_cells || Yes | chemo_concurrent_to_radiation || Yes | clinical_trial_indicator || Yes | coal_dust_exposure || Yes | columnar_mucosa_present || Yes | consistent_pathology_review || Yes | diagnosis_pathologically_confirmed || Yes | double_expressor_lymphoma || Yes | double_hit_lymphoma || Yes | environmental_tobacco_smoke_exposure || Yes | esophageal_columnar_metaplasia_present || Yes | gastric_esophageal_junction_involvement || Yes | goblet_cells_columnar_mucosa_present || Yes | haart_treatment_indicator || Yes | hepatitis_sustained_virological_response || Yes | history_of_tumor || Yes | lost_to_followup || Yes | lymphatic_invasion_present || Yes | metaplasia_present || Yes | mismatch_repair_mutation || Yes | necrosis_present || Yes | non_nodal_tumor_deposits || Yes | normal_tumor_genotype_snp_match || Yes | parent_with_radiation_exposure || Yes | perineural_invasion_present || Yes | pregnant_at_diagnosis || Yes | premature_at_birth || Yes | prior_treatment || Yes | progression_or_recurrence || Yes | rhabdoid_present || Yes | risk_factor_treatment || Yes | sarcomatoid_present || Yes | secondhand_smoke_as_child || Yes | synchronous_malignancy || Yes | treatment_effect_indicator || Yes | tumor_confined_to_organ_of_origin || Yes | undescended_testis_corrected || Yes | undescended_testis_history || Yes | vascular_invasion_present || yes | prior_malignancy || yes | progression_or_recurrence || yes | relative_with_cancer_history || yes | treatment_or_therapy	C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177574 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C29878 || C36037 || C39694 || C49236 || C81229	premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || coal_dust_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || alcohol_history
C	C177537	GDC Value Terminology	C60772	Smoothened Antagonist IPI-609	A semi-synthetic cyclopamine analogue and an inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon administration, smoothened antagonist IPI-609 targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.	Hedgehog Inhibitor IPI-609 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C62484	Chest Wall	The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura.	Chest Wall | biospecimen_anatomic_site || Chest Wall | treatment_anatomic_site || Chest wall | sites_of_involvement	C171435 || C173263 || C70729	biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_site
C	C177537	GDC Value Terminology	C64470	Absolute Basophil Count	The total number of white blood cells that are basophils. It is calculated by multiplying the white blood cell count by the percent of basophils in the differential white blood cell count.	Basophil | laboratory_test	C25294	laboratory_test
C	C177537	GDC Value Terminology	C64539	Yttrium Y 90 Resin Microspheres	An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression.	Y-90 Sirsphere | embolic_agent || Yttrium Y 90 Resin Microspheres | therapeutic_agents	C1909 || C97229	therapeutic_agents || embolic_agent
C	C177537	GDC Value Terminology	C65186	Malignant Pancreatic Insulinoma	An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin. It displays vascular invasion and metastasizes to other anatomic sites.	8151/3 | morphology || Beta cell tumor, malignant | primary_diagnosis || Insulinoma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C65190	Malignant Somatostatinoma	A neuroendocrine tumor arising from delta cells which produce somatostatin. It displays vascular invasion and metastasizes to other anatomic sites.	8156/3 | morphology || Somatostatin cell tumor, malignant | primary_diagnosis || Somatostatinoma, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C6569	Mesoblastic Nephroma	A low grade childhood congenital malignant neoplasm arising from the kidney. It is characterized by the presence of fibroblastic cells. The majority of cases occur in the first year of life. Complete excision is usually associated with an excellent prognosis.	8960/1 | morphology || Mesoblastic nephroma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C66750	Adult Granulosa Cell Tumor	A low-grade malignant sex cord-stromal tumor occurring in the ovary and rarely in the testis. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. In females, it affects middle aged to post-menopausal women. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course. In males, it is reported in the age range of 16-76 years and the average age at presentation is 44 years. A minority of patients have gynecomastia. Metastases have been reported in a minority of patients.	8620/1 | morphology || Adult granulosa cell tumor | primary_diagnosis || Granulosa cell tumor, adult type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C67015	Milligram per Deciliter	A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.	mg/dL | test_units || mg/dL | treatment_dose_units	C166199 || C67415	treatment_dose_units || test_units
C	C177537	GDC Value Terminology	C67306	Microgram per Liter	A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.	mcg/L | test_units || ng/mL | test_units	C67415	test_units
C	C177537	GDC Value Terminology	C6996	Uterine Corpus Adenomyosis	The growth of endometrial tissue inside the muscular wall of the uterine corpus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia.	Adenomyosis | additional_pathology_findings || Adenomyosis | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C71405	Aunt	The sister of your father or mother; the wife of your uncle.	Aunt | relationship_type	C83393	relationship_type
C	C177537	GDC Value Terminology	C73429	Identical Twin	Either of the two offspring resulting from a shared ovum.	Identical Twin Sibling | relationship_type	C83393	relationship_type
C	C177537	GDC Value Terminology	C74038	Vismodegib	An orally bioavailable, small molecule inhibitor of SMO and the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon oral administration, vismodegib targets, binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.	Vismodegib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C77064	Cevipabulin	A synthetic, water soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin, but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.	Cevipabulin | therapeutic_agents || Tubulin Binding Agent TTI-237 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C77641	Mesenteric Lymph Node	A lymph node located in the mesentery.	Lymph Node(s) Mesenteric | biospecimen_anatomic_site || Lymph Node(s) Mesenteric | treatment_anatomic_site || Mesenteric | lymph_node_involved_site || Mesenteric lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C77643	Paraaortic Lymph Node	A lymph node located adjacent to the lumbar region of the spine.	Lymph Node(s) Paraaortic | biospecimen_anatomic_site || Lymph Node(s) Paraaortic | treatment_anatomic_site || Paraaortic | lymph_node_involved_site || Paraaortic lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C77650	Submandibular Lymph Node	A lymph node located beneath the floor of the oral cavity.	Lymph Node(s) Submandibular | biospecimen_anatomic_site || Lymph Node(s) Submandibular | treatment_anatomic_site || Submandibular | lymph_node_involved_site || Submandibular lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C80281	EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	A diffuse large B-cell lymphoma originally described in patients older than 50 years, but it has been increasingly recognized in younger patients. Epstein-Barr virus is present in all cases. There is no known history of immunodeficiency or prior lymphoma.	9680/3 | morphology || EBV positive diffuse large B-cell lymphoma of the elderly | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C82431	Acute Myeloid Leukemia with NPM1 Mutation	An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.	9861/3 | morphology || Acute myeloid leukemia with mutated NPM1 | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C82433	Acute Myeloid Leukemia with CEBPA Mutation	An acute myeloid leukemia with non-germline mutations of the CEBPA gene.	9861/3 | morphology || Acute myeloid leukemia with mutated CEBPA | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C88143	External Iliac Lymph Node	A lymph node located along the external iliac artery.	Iliac-external | lymph_node_involved_site || Iliac-external | max_tumor_bulk_site || Lymph Node(s) Iliac-External | biospecimen_anatomic_site || Lymph Node(s) Iliac-External | treatment_anatomic_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C892	Smokeless Tobacco	Tobacco that is not smoked but used in another form such as chewing tobacco or snuff.	Smokeless Tobacco | exposure_type || Smokeless Tobacco | type_of_tobacco_used	C157103 || C177629	exposure_type || type_of_tobacco_used
C	C177537	GDC Value Terminology	C9003	Adrenal Cortical Adenoma	A benign neoplasm that can arise from any of the adrenal cortical layers.  It can be associated with the overproduction of glucocorticoids (Cushing's syndrome), androgenic or estrogenic steroids (adrenogenital syndrome), or mineralocorticoids (Conn's syndrome). (Sternberg Diagnostic Surgical Pathology, 3rd ed.)	8370/0 | morphology || Adrenal cortical adenoma, NOS | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9004	Benign Adrenal Cortical Neoplasm	A non-metastasizing neoplasm arising from the adrenal cortex.	8370/0 | morphology || Adrenal cortical tumor, benign | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9325	Adrenal Cortical Carcinoma	A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.	8370/3 | morphology || Adrenal cortical adenocarcinoma | primary_diagnosis || Adrenal cortical carcinoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9327	Malignant Adrenal Cortical Neoplasm	A primary or metastatic malignant neoplasm affecting the adrenal cortex.	8370/3 | morphology || Adrenal cortical tumor, malignant | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C9357	Hodgkin Lymphoma	A lymphoma, previously known as Hodgkin's disease, characterized by the presence of large tumor cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.	9650/3 | morphology || Hodgkin Lymphoma | disease_type || Hodgkin disease, NOS | primary_diagnosis || Hodgkin lymphoma, NOS | primary_diagnosis || Malignant lymphoma, Hodgkin | primary_diagnosis	C16457 || C176985 || C177621 || C2991	comorbidity || morphology || primary_diagnosis || disease_type
C	C177537	GDC Value Terminology	C9505	Dysembryoplastic Neuroepithelial Tumor	A glial-neuronal neoplasm located in the cortex. It occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO)	9413/0 | morphology || Dysembryoplastic neuroepithelial tumor | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C95177	Stage IIA1	A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures 4.0 cm or less in greatest dimension.	Stage IIA1 | ajcc_clinical_stage || Stage IIA1 | ajcc_pathologic_stage || Stage IIA1 | uicc_clinical_stage || Stage IIA1 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C95178	Stage IIA2	A stage term that applies to cervical cancer and indicates that the tumor invades beyond the uterus but not to the pelvic wall or to the lower third of vagina. There is no parametrial invasion.  The lesion is clinically visible and measures more than 4.0 cm in greatest dimension.	Stage IIA2 | ajcc_clinical_stage || Stage IIA2 | ajcc_pathologic_stage || Stage IIA2 | uicc_clinical_stage || Stage IIA2 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C95179	Stage IIIC1	A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades the stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue. There is regional lymph node metastasis to the pelvic lymph nodes.	Stage IIIC1 | ajcc_clinical_stage || Stage IIIC1 | ajcc_pathologic_stage || Stage IIIC1 | uicc_clinical_stage || Stage IIIC1 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C95180	Stage IIIC2	A stage term that applies to uterine corpus cancer and indicates that the tumor is confined to the corpus uteri, or it invades stromal connective tissue of the cervix but does not extend beyond the uterus, or it involves serosa and/or adnexa, vagina, or parametrial tissue.  There is regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.	Stage IIIC2 | ajcc_clinical_stage || Stage IIIC2 | ajcc_pathologic_stage || Stage IIIC2 | uicc_clinical_stage || Stage IIIC2 | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C95805	T1mi Stage Finding	A term that refers to a TNM finding of a primary tumor limited to the site of growth and indicates microinvasion only.	T1mi | ajcc_clinical_t || T1mi | ajcc_pathologic_t || T1mi | uicc_clinical_t || T1mi | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C95921	N0 (i-) Stage Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically, and immunohistochemistry is negative.	N0 (i-) | ajcc_clinical_n || N0 (i-) | ajcc_pathologic_n || N0 (i-) | uicc_clinical_n || N0 (i-) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95922	N0 (i+) Stage Finding	A regional lymph node TNM finding indicating that there are malignant cells in regional lymph node(s) no greater than 0.2 mm and are detected by hematoxylin and eosin stain or immunohistochemistry.	N0 (i+) | ajcc_clinical_n || N0 (i+) | ajcc_pathologic_n || N0 (i+) | uicc_clinical_n || N0 (i+) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95923	N0 (mol-) Stage Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and molecular analysis (RT-PCR) is negative.	N0 (mol-) | ajcc_clinical_n || N0 (mol-) | ajcc_pathologic_n || N0 (mol-) | uicc_clinical_n || N0 (mol-) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95925	N0 (mol+) Stage Finding	A regional lymph node TNM finding indicating that there is no evidence of regional lymph node metastasis histologically and by immunohistochemistry, but the molecular analysis (RT-PCR) is positive.	N0 (mol+) | ajcc_clinical_n || N0 (mol+) | ajcc_pathologic_n || N0 (mol+) | uicc_clinical_n || N0 (mol+) | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95929	N1bI Stage Finding	A regional lymph node TNM finding indicating that there is metastasis to 1-3 nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.	N1bI | ajcc_clinical_n || N1bI | ajcc_pathologic_n || N1bI | uicc_clinical_n || N1bI | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95935	N1bII Stage Finding	A regional lymph node TNM finding indicating that there is metastasis to four or more nodes.  The metastasis is greater than 2 mm and all are less than 20 mm.	N1bII | ajcc_clinical_n || N1bII | ajcc_pathologic_n || N1bII | uicc_clinical_n || N1bII | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95936	N1bIII Stage Finding	A regional lymph node TNM finding indicating that the tumor extends beyond the lymph node capsule and is less than 20 mm.	N1bIII | ajcc_clinical_n || N1bIII | ajcc_pathologic_n || N1bIII | uicc_clinical_n || N1bIII | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95937	N1bIV Stage Finding	A regional lymph node TNM finding indicating that the metastases to the lymph nodes are more than 20 mm.	N1bIV | ajcc_clinical_n || N1bIV | ajcc_pathologic_n || N1bIV | uicc_clinical_n || N1bIV | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95955	N1mi Stage Finding	A regional lymph node TNM finding indicating the presence of micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm).	N1mi | ajcc_clinical_n || N1mi | ajcc_pathologic_n || N1mi | uicc_clinical_n || N1mi | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C95956	cM0 (i+) Stage Finding	A distant metastasis TNM finding indicating that there is no evidence of distant metastasis clinically or by radiologic studies, but there are small numbers of cells detected by special studies in the blood and bone marrow, or there is tiny metastasis (no larger than 0.2 mm) detected in nonregional lymph nodes.	cM0 (i+) | ajcc_clinical_m || cM0 (i+) | ajcc_pathologic_m || cM0 (i+) | uicc_clinical_m || cM0 (i+) | uicc_pathologic_m	C177606 || C177607 || C188406 || C188415	ajcc_clinical_m || ajcc_pathologic_m || uicc_clinical_m || uicc_pathologic_m
C	C177537	GDC Value Terminology	C95957	Stage X	A stage term that is applied to patients who have not been evaluated, but are presumed to have cancer.	Stage X | ajcc_clinical_stage || Stage X | ajcc_pathologic_stage || Stage X | uicc_clinical_stage || Stage X | uicc_pathologic_stage	C177555 || C177556 || C188409 || C188446	ajcc_clinical_stage || ajcc_pathologic_stage || uicc_clinical_stage || uicc_pathologic_stage
C	C177537	GDC Value Terminology	C96025	Ta Stage Finding	A term that refers to a TNM finding of a primary, non-invasive, papillary cancer.	Ta | ajcc_clinical_t || Ta | ajcc_pathologic_t || Ta | uicc_clinical_t || Ta | uicc_pathologic_t	C177635 || C177636 || C188411 || C188448	ajcc_clinical_t || ajcc_pathologic_t || uicc_clinical_t || uicc_pathologic_t
C	C177537	GDC Value Terminology	C96026	N4 Stage Finding	A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N4 TNM finding depends on the specific type of cancer that it refers to; for example, for ocular adnexal lymphoma it refers to metastases to central lymph nodes.	N4 | ajcc_clinical_n || N4 | ajcc_pathologic_n || N4 | uicc_clinical_n || N4 | uicc_pathologic_n	C177611 || C177612 || C188408 || C188429	ajcc_clinical_n || ajcc_pathologic_n || uicc_clinical_n || uicc_pathologic_n
C	C177537	GDC Value Terminology	C98189	Retroperitoneal Lymph Node	A lymph node located in the retroperitoneal space.	Lymph Node(s) Retroperitoneal | biospecimen_anatomic_site || Lymph Node(s) Retroperitoneal | treatment_anatomic_site || Retroperitoneal | lymph_node_involved_site || Retroperitoneal lymph nodes | max_tumor_bulk_site	C171435 || C188396 || C33027 || C70729	biospecimen_anatomic_site || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_site
C	C177537	GDC Value Terminology	C99161	Utatrectinib	A tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. Upon administration, utatrectinib binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival.	Tropomyosin Receptor Kinase Inhibitor AZD7451 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C102995	Human Papillomavirus-26	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-26 may be associated with a high risk for cervical intraepithelial neoplasia.	26 | hpv_positive_type	C157110	hpv_positive_type
D	C177537	GDC Value Terminology	C103002	Human Papillomavirus-53	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-53 may be associated with a high risk for cervical intraepithelial neoplasia.	53 | hpv_positive_type	C157110	hpv_positive_type
D	C177537	GDC Value Terminology	C103009	Human Papillomavirus-82	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-82 may be associated with a high risk for cervical intraepithelial neoplasia.	82 | hpv_positive_type	C157110	hpv_positive_type
D	C177537	GDC Value Terminology	C126273	Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777	A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of diphtheria toxin fragment-IL-2 fusion protein E7777 binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, the agent is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death. E7777 has the same amino acid sequence as denileukin diftitox (DD), but has an increased purity profile and an increased percentage of monomeric, active protein, which improves its efficacy.	Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C126335	Androgen Receptor Antagonist SHR3680	An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, SHR3680 competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation.	Androgen Receptor Antagonist SHR3680 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C126422	VLP-encapsulated TLR9 Agonist CMP-001	An agent composed of an unmethylated CpG motif-rich G10 oligonucleotide, which is an agonist of toll-like receptor 9 (TLR9), encapsulated in noninfectious virus-like particles (VLPs), with potential immunostimulating and antineoplastic activities. Upon administration of CMP-001, the VLPs are specifically taken up by and release the oligonucleotide into antigen-presenting cells (APCs), including dendritic cells (DCs). In turn, the oligonucleotide binds to and activates intracellular TLR9. This stimulates immune signaling pathways, induces the innate immune system and may promote the immune system to attack tumor cells. VLPs stimulate the immune system. TLR9, a member of the TLR family, plays a key role in both pathogen recognition and the activation of innate immunity.	VLP-encapsulated TLR9 Agonist CMP-001 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C139692	Cervical Cancer cT1b1 TNM Finding v8	Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)	T1b1 | ajcc_clinical_t	C177635	ajcc_clinical_t
D	C177537	GDC Value Terminology	C139693	Cervical Cancer cT1b2 TNM Finding v8	Cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)	T1b2 | ajcc_clinical_t	C177635	ajcc_clinical_t
D	C177537	GDC Value Terminology	C139696	Cervical Cancer cT2a1 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)	T2a1 | ajcc_clinical_t	C177635	ajcc_clinical_t
D	C177537	GDC Value Terminology	C139697	Cervical Cancer cT2a2 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)	T2a2 | ajcc_clinical_t	C177635	ajcc_clinical_t
D	C177537	GDC Value Terminology	C139711	Cervical Cancer pT1a1 TNM Finding v8	Invasive cervical carcinoma with measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. (from AJCC 8th Ed.)	T1a1 | ajcc_clinical_t || T1a1 | ajcc_pathologic_t	C177635 || C177636	ajcc_clinical_t || ajcc_pathologic_t
D	C177537	GDC Value Terminology	C139712	Cervical Cancer pT1a2 TNM Finding v8	Invasive cervical carcinoma with measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less. (from AJCC 8th Ed.)	T1a2 | ajcc_clinical_t || T1a2 | ajcc_pathologic_t	C177635 || C177636	ajcc_clinical_t || ajcc_pathologic_t
D	C177537	GDC Value Terminology	C139714	Cervical Cancer pT1b1 TNM Finding v8	Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)	T1b1 | ajcc_pathologic_t	C177636	ajcc_pathologic_t
D	C177537	GDC Value Terminology	C139715	Cervical Cancer pT1b2 TNM Finding v8	Cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)	T1b2 | ajcc_pathologic_t	C177636	ajcc_pathologic_t
D	C177537	GDC Value Terminology	C139718	Cervical Cancer pT2a1 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)	T2a1 | ajcc_pathologic_t	C177636	ajcc_pathologic_t
D	C177537	GDC Value Terminology	C139719	Cervical Cancer pT2a2 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)	T2a2 | ajcc_pathologic_t	C177636	ajcc_pathologic_t
D	C177537	GDC Value Terminology	C140651	Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8	Choroidal and ciliary body melanoma, any tumor size category with extraocular extension more than 5 mm in largest diameter. (from AJCC 8th Ed.)	T4e | ajcc_clinical_t || T4e | ajcc_pathologic_t	C177635 || C177636	ajcc_clinical_t || ajcc_pathologic_t
D	C177537	GDC Value Terminology	C143251	Anti-CD123 ADC IMGN632	An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.	Anti-CD123 ADC IMGN632 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C150552	SERD G1T48	An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD G1T48 specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.	SERD G1T48 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C154553	SLCT Inhibitor GNS561	An orally available, quinolone-derived, small molecule inhibitor of an as of yet not disclosed solute carrier transporter (SLCT), with potential antineoplastic activity. Upon oral administration, GNS561 demonstrates multiple cellular effects including inhibition of SLCT activity, induction of apoptosis via caspase 3/7 activation, and inhibition of autophagy through lysosomal disruption. Several SLCTs are upregulated in cancer and serve as tumor promoters. Over-expression of SLCT in some tumors is associated with stemness features and may be associated with poor outcomes. Inhibition of autophagy and induction of apoptosis may potentially inhibit tumor cell growth.	SLCT Inhibitor GNS561 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C155735	H3.X Gene	Human H3.X gene is located in the vicinity of 5p15.1 and is approximately 0.4 kb in length. This pseudogene has no formally documented products.	H3.X | histone_variant	C177620	histone_variant
D	C177537	GDC Value Terminology	C156054	Human Papillomavirus-63	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-63 may be associated with a risk for cervical cancer.	63 | hpv_positive_type	C157110	hpv_positive_type
D	C177537	GDC Value Terminology	C156055	Human Papillomavirus-70	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-70 may be associated with a high risk for cervical cancer.	70 | hpv_positive_type	C157110	hpv_positive_type
D	C177537	GDC Value Terminology	C168584	CD28/ICOS Antagonist ALPN-101	An Fc fusion protein comprised of a human inducible T-cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD) that binds to both inducible T-cell costimulator (ICOS; CD278) and cluster of differentiation 28 (CD28), with potential immunomodulating activity. Upon administration, CD28/ICOS antagonist ALPN-101 targets and binds to both CD28 and ICOS expressed on certain T-cells. This prevents the activation of CD28 and ICOS by its ligands, thereby blocking the two T-cell costimulatory pathways and the resulting T-cell activation. CD28 is involved in initiation of the pathogenic process in graft versus host disease (GVHD). Following initial activation, CD28 is often downregulated while ICOS is upregulated, possibly sustaining GVHD. Dual blockade of CD28 and ICOS may be superior to individual blockade of CD28 or ICOS alone. 	CD28/ICOS Antagonist ALPN-101 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C170815	BiTE Antibody AMG 910	A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, AMG 910 targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.	BiTE Antibody AMG 910 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C179442	N6-Methyladenine RNA Analysis	An assay that quantitates the amount and identifies the location of N6-methyladenine modifications within an RNA sequence.	m6A RNA Methylation | experimental_strategy || m6A RNA Methylation | library_strategy	C177618 || C43622	library_strategy || experimental_strategy
D	C177537	GDC Value Terminology	C2509	Hu14.18-IL2 Fusion Protein EMD 273063	A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 EMD 273063 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses.	Hu14.18-IL2 Fusion Protein EMD 273063 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C27886	Type 1 Papillary Renal Cell Carcinoma	A papillary renal cell carcinoma characterized by the presence of papillae covered by small cells with scant amount of cytoplasm. The cells are arranged in a single layer on the basement membrane of the papillae.	Type 1 | papillary_renal_cell_type		
D	C177537	GDC Value Terminology	C27887	Type 2 Papillary Renal Cell Carcinoma	A papillary renal cell carcinoma characterized by the presence of papillae covered by cells of a higher nuclear grade as compared to type 1 papillary renal cell carcinoma. The cells have eosinophilic cytoplasm and pseudostratified nuclei.	Type 2 | papillary_renal_cell_type		
D	C177537	GDC Value Terminology	C2879	Neoplasm of the Diffuse Neuroendocrine System	A tumor made up of cells with APUD properties.	8248/1 | morphology || Apudoma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C5325	Intestinal Gangliocytic Paraganglioma	A usually indolent, extra-adrenal paraganglioma affecting the intestine. Patients may present with gastrointestinal hemorrhage. Unlike the conventional paragangliomas, this tumor has a peculiar morphologic appearance; it consists of a mixture of epithelioid neuroendocrine cells, Schwann-like cells, and ganglion cell-like elements.	8683/0 | morphology || Gangliocytic paraganglioma | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
D	C177537	GDC Value Terminology	C61566	Tubulin Binding Agent TTI-237	A small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity. With a novel mechanism of action distinct from the action of other vinca alkaloid compounds, TTI-237 specifically binds to tubulin at the vinca site, and promotes the polymerization of tubulin into microtubules. TTI-237 stabilizes tubulin and inhibits microtubule disassembly. This results in cell cycle arrest at the G2/M phase, and leading to cell death.	Tubulin Binding Agent TTI-237 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C74008	CD40 Agonist Monoclonal Antibody CP-870,893	A fully human monoclonal antibody (mAb) agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Similar to the CD40 ligand (CD40L or CD154), CD40 agonist monoclonal antibody CP-870,893 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent may activate CD40 present on the surfaces of some solid tumor cells, resulting in apoptosis and decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and some solid tumors, mediating both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.	CD40 Agonist Monoclonal Antibody CP-870,893 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C88290	Short Chain Fatty Acid HQK-1004	A short chain fatty acid (SCFA) with potential herpes simplex virus thymidine kinase gene (HSV-TK)-inducing activity. Upon administration, short chain fatty acid HQK-1004 may induce the expression of thymidine kinase (TK) by a silenced HSV-TK, which may activate a co-administered antiviral prodrug such as ganciclovir, resulting in the destruction of virally-infected cancer cells.	Short Chain Fatty Acid HQK-1004 | therapeutic_agents	C1909	therapeutic_agents